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ABSTRACT 
 
EXAMINATION OF PROMOTER HYPERMETHYLATION PATTERNS IN 
MAGNETICALLY ENRICHED EXFOLIATED BREAST MILK EPITHELIAL CELLS 
 
February 2010 
 
CHUNG M. WONG 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed By: Kathleen F. Arcaro 
 
 
Suppression of genes involved in DNA repair, tumor suppression and 
detoxification through epigenetic modifications has been implicated in the etiology of 
cancer. As such analysis of promoter methylation patterns in genes frequently 
downregulated in breast cancer in non-cancerous subjects may serve as an indicator of 
breast cancer risk.  CpG-island hypermethylation of single genes has been detected in 
cells isolated from nipple aspirate and ductal lavage, yet both isolation methods yield 
insufficient cells to complete an extensive analysis on any one donor sample.  
As an alternative we have turned to magnetic separation of human mammary 
epithelial cells from breast milk.  Initial studies with these cells, which are detailed in 
chapter one, show that a breast milk sample provides sufficient epithelial cells to isolate 
high quality RNA for gene expression analyses or genomic DNA for methylation analysis 
of multiple genes. Using quantitative RT-PCR of RNA collected from these samples we 
detected differences in the mRNA levels for six genes known to be downregulated in 
breast cancers: BRCA1, p16, CDH1, TMS-1, GSTPi, and SFRP1. Additionally using 
methyl-specific PCR (MSP) we assayed for a small panel of genes frequently methylated 
in cancer and found them to be unmethylated in the few breast milk samples examined.  
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However, given the small number of CpG sites which can be assayed by the MSP 
technique it is not surprising that methylation was not detected in disease-free subjects.  
With methods for collecting breast milk samples and processing them for genetic 
material established we turned to a more comprehensive study of DNA methylation in 
larger population of donors which is detailed in chapter two.  Utilizing a highly sensitive 
and highly quantitative methylation analysis technique known as Pyrosequencing we 
examined age-related methylation patterns for RASSF1A, TMS-1, CDH1, SFRP1, 
GSTPi, and CRBP1 in genomic DNA purified from exfoliated epithelial cells 
magnetically enriched from breast milk (n=111) and whether the protective effects 
conveyed by early pregnancy could be partly due to decreases in DNA hypermethylation.  
Although firm answers about early pregnancy were inconclusive based on our sample 
pool, this body of work lays down a solid foundation for future studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 vi  
 
TABLE OF CONTENTS 
                 Page 
ACKNOWLEDGEMENTS................................................................................... iii 
 
ABSTRACT........................................................................................................... iv 
 
CHAPTER 
 
1:  OVERALL INTRODUCTION...........................................................................1 
  
2:  EXAMINATIONS OF MAGNETIC ENRICHMENT FOR EPITHELIAL 
CELLS FROM BREAST MILK AND SUBSEQUENT GENE EXPRESSION 
AND PRELIMINARY METHYLATION ANALYSIS..........................................4 
 
Introduction..............................................................................................................4 
Material and Methods ..............................................................................................5 
  
 Acquisition of Donor Samples.....................................................................5 
 Milk Sample Processing ..............................................................................5 
 Magnetic Antibody Cell Separation (MACS)..............................................6 
 Cell Culture..................................................................................................6 
 Fluorescence Activated Cell Sorting (FACS) Analysis...............................7 
 Total RNA Isolation.....................................................................................8 
 Quantitative Reverse Transcription Real-Time PCR...................................9 
 Preliminary Methylation Analysis .............................................................10 
 Statistical Analysis.....................................................................................12 
 Sample Summary.......................................................................................12 
 
Results ....................................................................................................................12 
  
 Sample Processing .....................................................................................12 
 RNA Isolation ............................................................................................13 
 Preliminary Gene Expression Analysis .....................................................14 
 Methyl-Specific PCR.................................................................................15 
 FACS Analysis...........................................................................................15 
 Enriched Fraction Versus Depleted Fraction Expression ..........................18 
 
Discussion ..............................................................................................................19 
 
3:  EXAMINATION OF PROMOTOR HYPERMETHYLATION PATTERNS 
IN ENRICHED EXFOLIATED EPITHELIAL CELLS IN BREAST MILK 
BY PYROSEQUENCING.....................................................................................46 
 
Introduction............................................................................................................46 
Materials and Methods...........................................................................................50 
 Acquisition of Donor Samples...................................................................50 
 vii  
 
 Milk Sample Processing ............................................................................50 
 Magnetic Antibody Cell Separation (MACS)............................................51 
 DNA Isolation............................................................................................51 
 Bisulfite Modification of DNA..................................................................52 
 Pyrosequencing Primers.............................................................................52 
 PCR Amplification for Pyrosequencing Analysis .....................................53 
 Statistical Analysis.....................................................................................53 
 
Results ....................................................................................................................54 
  
 Sample Processing .....................................................................................54 
 DNA Isolation............................................................................................54 
 Pyrosequencing Analysis ...........................................................................55 
 Examination of Enriched Versus Depleted Fraction Methylation.............59 
 Early Pregnancy and Parity........................................................................60 
 
Discussion ..............................................................................................................61 
 
References..............................................................................................................95 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii  
 
LIST OF TABLES 
 
Table   Page   
 
2.1 Quantitative Real-Time RT-PCR primers for use in gene expression analysis...... 25 
 
2.2 Primers utilized for Methyl-Specific PCR analysis.  From House et al. 2003. ...... 26 
 
2.3 Cell counts of total and epithelial-enriched fractions and donor demographics 
of 54 breast milk samples collected in 2004................................................................. 27 
 
2.4 Total µg of RNA for each of the first 54 breast milk samples and their 
respective 260/280 absorbance ratio............................................................................. 28 
 
2.5 Calculated positive fold change of the epithelial-enriched (+, green) versus 
depleted cell fractions (-, red) ....................................................................................... 29 
 
3.1 Pyrosequencing primers and cycle conditions........................................................ 67 
 
3.2 Cell counts of total and epithelial-enriched fractions along with donor 
demographics of 102 samples utilized in the subsequent DNA isolation..................... 68 
 
3.3 Statistical data extracted from figure 3.18 examining the effect of early 
pregnancy on mean methylation levels......................................................................... 69 
 
3.4 Statistical data extracted from figure 3.19 examining the effect of parity on 
mean methylation levels ............................................................................................... 70 
 
3.5 Statistical data extracted from figure 3.20 examining the combined effect of 
parity and lactation on mean methylation levels........................................................... 71 
 
3.6 Statistical data extracted from figure 3.21 examining the combined effect of 
parity and lactation on mean methylation levels........................................................... 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix  
 
LIST OF FIGURES 
 
Figures          Page 
        
2.1  Relationship between total cell count per mL of breast milk and (a) the 
donor’s age and (b) nursing length ..............................................................................30 
 
2.2  Relationship between enriched cell count per mL of breast milk and (a) the 
donor’s age and (b) nursing length ..............................................................................31 
 
2.3  Relationship between cell yield and RNA purity .................................................32 
 
2.4  Expression of a panel of genes frequently hypermethylated and silenced in 
breast cancer.................................................................................................................33 
 
2.5  Expression of luminal and basal cell markers in the epithelial-enriched cell 
fraction of breast milk..................................................................................................34 
 
2.6  Methyl-Specific PCR results for five genes commonly found to be 
methylated in cancer ....................................................................................................35 
 
2.7  Flow cytometry analysis of mixing experiment of MCF-10A (epithelial) 
and Jurkat (T-lymphocyte) cells separated by magnetic antibody cell separation ......36 
 
2.8  Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 104 cell fractions .............................................................................................37 
 
2.9  Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 116 cell fractions .............................................................................................38 
 
2.10 Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 117 cell fractions .............................................................................................39 
 
2.11 Flow cytometry analysis of Annexin-V apoptotic staining of milk sample 
117................................................................................................................................40 
 
2.12 Flow cytometry analysis of intracellular cytokeratins 7, 8, 18 and 19 in 
MCF-10A cells permeabilized with .5% tween 20......................................................41 
 
2.13 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk sample 126 fractions............................................................................................42 
 
2.14 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk sample 127 fractions............................................................................................43 
 
 x  
 
2.15 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk 129 fractions ........................................................................................................44 
 
2.16 Gene expression comparison of a) MUC-1 and b) CD45 expression in 
both the enriched (+) and depleted (-) cell fractions magnetically separated 
from six breast milk samples .......................................................................................45 
 
3.1 PCR bias testing of SFRP1 was carried out to ensure equal amplification 
of both methylated and unmethylated templates ..................................................73 
 
3.2 PCR bias testing of CRBP1 which was carried out to ensure equal 
amplification of both methylated and unmethylated templates ............................74 
 
3.3 PCR bias testing of TMS-1 which was carried out to ensure equal 
amplification of both methylated and unmethylated templates ............................75 
 
3.4 Histograms of donor and infant demographics .....................................................76 
 
3.5 Relationship between total cells per mL of breast milk and (a) the donor’s 
age and (b) nursing length.....................................................................................77 
 
3.6 Relationship between enriched epithelial cells per mL of breast milk and 
(a) the donor’s age and (b) nursing length ............................................................78 
 
3.7 Relationship between enriched epithelial yield and (a) DNA yield and (b) 
DNA purity ...........................................................................................................79 
 
3.8 Example Pyrogram readouts for RASSF1A .........................................................80 
 
3.9 Mean methylation scores for each of six genes analyzed with age ......................81 
 
3.10 CpG site-specific analysis of SFRP1 promoter methylation ...............................82 
 
3.11 CpG site-specific analysis of CRBP1 promoter methylation ..............................83 
 
3.12 CpG site-specific analysis of TMS-1 promoter methylation ...............................84 
 
3.13 CpG site-specific analysis of CDH1 promoter methylation ................................85 
 
3.14 CpG site-specific analysis of GSTPi promoter methylation................................86 
 
3.15 CpG site-specific analysis of RASSF1A promoter methylation .........................87 
 
3.16 Comparison of the RASSF1A mean methylation levels in enriched 
fraction versus depleted fraction cells...................................................................88 
 
 xi  
 
3.17 Mean RASSF1A methylation scores of the (a) enriched and (b) depleted 
fractions with respect to age. ................................................................................89 
 
3.18 Examination of how early pregnancy affects DNA hypermethylation................90 
 
3.19 Examination of how parity may affect DNA hypermethylation..........................91 
 
3.20 Examination of how the combined effects of early pregnancy and parity 
may affect DNA hypermethylation as compared to women who have only 
given birth once.....................................................................................................92 
 
3.21 Examination of how lactation, but not early pregnancy would affect mean 
methylation scores ................................................................................................93 
 
3.22 Reproducibility test of pyrosequencing analysis at low methylation levels ........94 
 1  
 
CHAPTER 1 
 
  OVERALL INTRODUCTION 
 
 Breast cancer is a devastating illness that affects tens of thousands of American 
women each year.  In 2008, it is estimated that 182,460 women will be diagnosed and 
40,480 women will die of this disease (Ries et al. 2008).   
 Deregulation of the epigenome is now recognized as a major mechanism involved 
in the development and progression of many human diseases including breast cancer 
(Baylin et al. 2005). There is also mounting evidence that the epigenetic landscape in 
humans constantly shifts as a result of normal aging (Fraga et al. 2007) and 
environmental influence (Jirtle et al. 2007).  DNA methylation is one such epigenetic 
modification for which we are beginning to understand the scope and magnitude of its 
effects on human health.  
 DNA methylation refers to the addition of a methyl group to the 5 carbon position 
of the cytosine pyrimidine ring.  This covalent attachment results in the recruitment of 
methyl binding proteins which in turn interact with histone deacetylases to maintain a 
condensed DNA structure that prohibits the binding of transcription machinery (Newell-
Price et al. 2000).  The epigenetic modification of DNA methylation does not involve any 
changes to the sequence of the DNA itself.  As such, a special technique known as 
bisulfite modification was developed which allows for the sensitive detection of 
methylated cytosine residues.  Treatment with sodium bisulfite deaminates cytosine to 
thymine with very high efficiency, however methylated cytosines are protected from this 
conversion and remain as cytosine.  This distinction allows for analysis of methylation 
patterns by using primers designed to bind to either methylated or unmethylated 
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templates (methyl-specific PCR), or more recently mass spec and sequencing analysis 
techniques (Fraga et al. 2002). 
 In the context of DNA methylation, sequences within the genome can be 
classified into either CpG (cytosine phosphodiester-bond guanine) poor regions or CpG 
rich “islands”.  CpG islands are found in the promoters of many but not all genes and are 
typically unmethylated in healthy cells.  In cancer these CpG islands often become 
aberrantly methylated resulting in changes to the chromatin structure and subsequent 
transcriptional silencing of many tumor suppressors, proto-oncogenes, and vital cell cycle 
genes disrupting normal cellular function (Baylin et al. 2005).  The role of promoter 
hypermethylation in cancer has been well established with a list of affected genes that 
grows daily.   These patterns of aberrant methylation are detectable far in advance of 
disease onset and correlate to known risk factors (Lewis et al. 2005).   As such, CpG 
island promoter hypermethylation has quickly become a candidate biomarker for breast 
cancer risk assessment. 
 Euhus et al (2007) has shown that promoter methylation patterns in normal breast 
tissue correlate highly to the widely used Gail model of breast cancer risk.  One gene 
which was found to be highly correlative is Ras association domain family 1A 
(RASSF1A).  RASSF1A is a tumor suppressor gene that normally functions in regulating 
mitosis, cell cycle and apoptosis in response to mitogenic or apoptotic stimuli.  In their 
study, fine needle aspiration (FNA) of benign breast samples from 70% of unaffected 
women at high risk for breast cancer (Gail risk index >2) had methylated RASSF1A 
promoters compared with only 29% from women at low or intermediate risk (Euhus et al. 
2007).   
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 Ductal fluid and breast tissue biopsies provide rich sources of biomarkers for 
early detection and breast cancer risk assessment in asymptomatic women without 
suspicious lesions.  Recently invasive core biopsies have given way to non-invasive 
methods of obtaining epithelial cells such as nipple-aspirate fluid (NAF), ductal lavage 
(DL) or periareolar fine-needle aspiration (PFNA).  These techniques, although powerful, 
are still limiting in that trained personal are required to oversee the procedures and the 
cellular yields are typically quite low. (Klein et al. 2002)  
 As an alternative source of epithelial cells we have turned to breast milk.  In 
contrast to other cell isolation techniques a single breast milk sample can yield millions 
of exfoliated epithelial cells which can be utilized in a variety of molecular studies.  
Additionally, the breast milk itself can be examined for bioconcentrated environmental 
pollutants and resulting metabolites which have accumulated over a donor’s lifetime. 
This dual use of breast milk in both molecular and chemical analyses make it an 
attractive source for molecular epidemiologic studies. 
 We propose that DNA hypermethylation  of promoter CpG island in a panel of 
cancer related genes -- Ras association domain family 1A (RASSF1A), Secreted Frizzle 
Related Protein 1 (SFRP1), E-Cadherin (CDH1), Glutathione-S-Transferase pi (GSTPi), 
Target of Methylation Silencing 1 (TMS-1), and Cellular Retinol Binding Protein 1 
(CRBP1) -- are detectable in exfoliated epithelial cells from breast milk.  Furthermore we 
propose that methylation status of these gene promoters is correlated with increased 
breast cancer risk.  
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CHAPTER 2   
 
EXAMINATIONS OF MAGNETIC ENRICHMENT FOR EPITHELIAL CELLS 
FROM BREAST MILK AND SUBSEQUENT GENE EXPRESSION AND 
PRELIMINARY METHYLATION ANALYSIS 
 
Introduction 
 To test the feasibility of using breast milk as a source of biomarker material a 
number of questions needed to be addressed.  First, is it possible to enrich for epithelial 
cells out of a total cell fraction containing multiple cell types?  Second, would it be 
possible to harvest RNA in sufficient quantity to carry out multiple analyses of candidate 
genes?  And third, would subsequent gene expression analysis detect any significant 
changes indicating the usefulness of breast milk epithelial cells in biomarker studies? 
 (Clarke et al. 1994) first described the use of paramagnetic beads for purification 
of epithelial cells from mixed populations.  Following their example we utilized a 
magnetic bead conjugated with an antibody to the epithelial cell adhesion molecule 
(EpCAM) also known as Human Epithelial Antigen (HEA)-125 which has specificity 
towards cells of epithelial origin.  These antibodies were then incubated with the total cell 
fraction from breast milk and subsequently captured on a paramagnetic column to be 
eluted in a later step.   This method was used to select and enrich for the epithelial cells. 
 To address some of the questions above a number of preliminary experiments 
were designed to verify the magnetic antibody cell separation (MACS) enrichment of 
epithelial cells, identify the type of epithelial cells being studied, determine gene 
expression of a small panel of breast cancer related genes, and finally perform some 
preliminary examinations of promoter hypermethylation. 
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Materials and Methods 
Acquisition of Donor Samples 
 Nursing donors, recruited largely from western Massachusetts, were asked to 
provide a milk sample of approximately 100 mL and to complete a comprehensive 
personal information and lifestyle questionnaire.  Human subject use, which included 
informed consent, was approved by the University of Massachusetts, Institutional Review 
Board, Human Research Protection Office (HRPO).    
Milk Sample Processing 
 Fresh breast milk samples were collected within an hour of pumping and 
transported to the lab where they were immediately processed.  The volume of the sample 
was first recorded and a small aliquot of milk (3 mL) frozen (-80C) for toxicological 
analysis.  The remaining breast milk was diluted 1:1 in sterile room temperature 
phosphate buffered saline (PBS) to reduce the viscosity of the liquid.  For the first 
samples used for RNA and DNA isolation total cells in the sample were pelleted at 200 G 
for 10 minutes.  For the later samples used in flow cytometry and characterization of the 
separated populations total cells were pelleted at 1000 G for 10 minutes resulting in 
improved cellular yields.  The supernatant from this initial spin, including all of the milk 
fat, was manually transferred into an acid washed collection bottle and archived (-80C) 
for later chemical extraction.  The cell pellet was then resuspended in a large volume of 
PBS.  Repeated washing and centrifugation steps (between 3-5 repetitions depending on 
sample viscosity) were performed to remove as much milk as possible. The washed cell 
pellet was then resuspended in 1 mL of degassed 2 mM ethylenediaminetetraacetic acid 
(EDTA) / 0.5% bovine serum albumin (BSA) in PBS.  A small aliquot of the resuspended 
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cells was diluted 1:1 with trypan blue and used to determine total cells in the sample by 
hemocytometer counts 
Magnetic Antibody Cell Separation (MACS) 
 The cell suspension was centrifuged for 10 minutes at 210 G to pellet cells.  For 
less than 1x107 cells, the pellet was resuspended in 60 µl of degassed 2 mM EDTA/0.5% 
BSA in PBS, with 20 µl of epithelial-specific direct MACS HEA-125 microbeads 
(Miltenyi Biotec, Germany) and 20 µl of Fc blocking reagent (Miltenyi Biotec, 
Germany).  Volumes were scaled up for larger numbers of cells. The resulting cell-
microbead suspension was incubated for 15 minutes at 4ºC.  After the incubation step, the 
total volume was brought up to 1 mL of degassed 2 mM EDTA/0.5% BSA in PBS and 
the suspension was again centrifuged at 210 G for 10 minutes to pellet the cells.  The 
supernatant was decanted and the pellet was resuspended in 0.5 mL of degassed PBS.  
Cell separation using the MACS paramagnetic column & stand (Miltenyi Biotec, 
Germany) was performed as indicated in the manufacturer’s protocol with both 
epithelial-depleted (negative) and epithelial-enriched (positive) populations being 
isolated.  The cells in the resulting positive fraction were again counted using a 
hemocytometer to ascertain the number of enriched exfoliated breast epithelial cells.  
Both the positive and negative fractions were pelleted at 210 G for 10 minutes to be 
utilized in downstream applications.  
Cell Culture 
 Cell cultures were maintained in a 37oC humidified incubator with 5% CO2.  
Jurkat cells were kindly provided by Dr. Barbara Osborne (UMASS, Amherst MA).  
MCF-7 & MCF-10A cells were purchased from American Type Culture Collection 
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(ATCC, Manassas VA).  184 cells were received from Dr. Martha Stampfer (Lawrence 
Berkeley National Laboratory, Berkeley CA).  Human mammary epithelial cells (HMEC) 
were kindly provided by Dr. Sallie Smith Schneider (Baystate Medical Center (PVLSCI), 
Springfield MA).  Cell cultures were maintained in complete growth medium and 
subcultured according to the appropriate manufacturer’s/supplier’s protocols. 
Fluorescence Activated Cell Sorting (FACS) Analysis 
Extracellular Staining 
 One million cells from each of the total unseparated, epithelial-enriched and 
epithelial-depleted cell fractions were washed and resuspended in 100 µl of staining 
buffer (PBS + 2% fetal calf serum (FCS)  + 0.1% sodium azide).  Each fraction was then 
incubated with 20 µl of fluoroscein isothiocyanate (FITC) conjugated CD326 (Epithelial 
Specific Cell Adhesion Molecule)  (BD Pharmingen, San Jose CA) and/or CD45 
phycoerythrin (PE) conjugate (Leukocyte Common Antigen) BD Pharmingen, San Jose 
CA) for 15 minutes at 4ºC in the dark.   The cell suspensions were then fixed using 
freshly prepared 2% paraformaldehyde at 4ºC in the dark and analyzed within 24 hrs on a 
BD Facscaliber using Cellquest software (BD Biosciences, San Jose CA) with 
appropriate single stained and unstained controls.  From start to finish the process of cell 
separation, staining and finally fixation was approximately 3.5 hours from the time the 
sample arrived in the lab. 
Apoptosis Detection 
 Using the Annexin V-PE Apoptosis Detection Kit (BD Pharmingen, San Jose CA) 
1x106 cells from each of the total unseparated, epithelial-enriched and epithelial-depleted 
cell fractions were washed twice with cold PBS and resuspended in 100 µl of 1x binding 
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buffer.  5 µl of Annexin V-PE and 5 µl of 7-AAD was added to each tube which was 
subsequently incubated at room temperature for 15 minutes in the dark.  After this 
incubation period 400 µl of 1x binding buffer was added to each tube and the cells were 
analyzed within an hour on a BD Facscaliber using Cellquest software (BD Biosciences, 
San Jose CA) with appropriate single stained and unstained controls.  Due to 
ineffectiveness of the 7-AAD’ staining propidium iodide was utilized as an alternative 
stain to determine the extent of cellular necrosis in the total cell fraction.  Methods were 
as described in (Riccardi et al. 2006). 
Intracellular Staining 
 One million cells from each of the total unseparated, epithelial-enriched and 
epithelial-depleted cell fractions were washed with PBS and fixed using freshly prepared 
2% paraformaldehyde for 30 minutes in the dark.  The cell suspensions were then washed 
once with PBS and resuspended in the permeabilization buffer (PBS + 2% FCS + 0.1% 
NaN3 + 0.5% Tween 20) for 15 minutes at room temperature.  The suspensions were then 
centrifuged for 5 minutes at 200 G and resuspended in 90 µl of the permeabilization 
buffer.  10 µl of Anti-Cytokeratin (CK3-6H5)(Miltenyi Biotec, Germany) with reactivity 
to cytokeratins 7, 8, 18, and 19 was added to the suspension and incubated for 10 minutes 
in the dark at room temperature.  Analysis was performed within 24 hrs on a BD 
Facscaliber using Cellquest software (BD Biosciences, San Jose CA) with appropriate 
single stained and unstained controls.  
Total RNA Isolation 
 Tri-Reagent (Molecular Research Center, Cincinnati OH) RNA isolation was 
performed as per manufacterer’s instructions.  Contaminating DNA was subsequently 
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removed from each isolated sample with a Turbo DNase Free (Ambion, Austin TX) 
treatment.  RNA was quantified and assayed for purity (A260/A280) using a Genequant 
(Amersham Biosciences, Buckinghamshire UK) and archived at -80oC.  Attempts were 
made to perform standard Acid-Phenol:Chloroform, pH 4.5 (with isoamyl alcohol, 
125:24:1)(Ambion, Austin TX) extractions to remove some of the contaminating protein 
on a small number of samples. 
Quantitative Reverse Transcription Real-Time PCR 
 Levels of mRNA expression were quantified by real-time PCR using the 
LightCycler System (Roche Molecular Diagnostics).  Primers were designed (Table 2.1) 
using Primer3 and ordered through Integrated DNA Technologies (Coralville IA).  
Reverse transcription and subsequent cDNA amplification was performed in a single step 
using One-Step RT-PCR Kit (Qiagen, Valencia CA).  Amplification of cDNA was 
performed as in Fasco et al, 2003.  Briefly, master mixes were prepared at 4oC and in 
multiples of 50 µl containing: 33 µl water; 10 µl of 5x buffer (supplied); 2 µl of dNTP 
solution (supplied); 2 µl of enzyme mixture (supplied); 1 µl of primer mixture (25 µM 
each) and 2 µl of SYBR green I (Invitrogen, Carlsbad CA) diluted 1/100 as a stock and 
1/50 before use in water.  Aliquots (14.3 µl) were distributed into capillaries pre-cooled 
to 4 oC, and 0.75 µl total RNA was added to each.  Unknown samples contained 0.1 µg 
total RNA per µl for all genes assayed.  Reverse transcription was performed at 50 oC for 
30 minutes followed by a 15 min 95 oC heating step to inactivate the reverse 
transcriptases and activate the Taq polymerase.  Amplification occurred over 45 cycles 
with the cycling times for denaturation (95 oC), annealing (60 oC), and extension (72 oC) 
were 15, 15, and 30 s respectively.  Fluorescence at the end of each amplification cycle 
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was acquired at 5 oC below the start of the product melting temperature for each 
amplified target.  Standard curves for the various genes of interest were generated from 
10-fold dilutions of total RNA isolated from MCF-7, TMX2-28 or Jurkat cells prior to 
the initiation of the experiment.  A standard RNA sample was included with the unknown 
samples to account for run to run variation in comparison to the standard curves.  All 
expression data were then normalized to the housekeeping gene hypoxanthine guanine 
phosphoribosyl transferase (HPRT) (de Kok et al. 2005) to account for slight variations 
of RNA concentrations. 
Preliminary Methylation Analysis 
DNA Isolation 
 Total genomic DNA was isolated from the epithelial-enriched fraction of four 
breast milk samples using the QIAamp DNA isolation kit (Qiagen, Valencia CA) with the 
addition of RNAse A and Proteinase K digestion steps as per manufacterer’s suggestions.  
DNA was quantified and assayed for quality using a Genequant (Amersham Biosciences, 
Buckinghamshire UK). 
Methylated and Non-Methylated DNA controls 
 An in vitro methylated control was generated using HMEC DNA by incubation 
with m.Sssi methylase (NEB, Ipswich, MA).  Briefly, 5 µg of HMEC DNA was 
incubated 1µL S-adenosylmethionine (32mM), 1µL m.Sssi methylase (4,000U/ml), 5µL 
of 10 X NEB buffer 2 and brought up to a total reaction volume of 50µL with nuclease-
free water.  This mixture was then incubated at 37oC for 4 hours.  Following the 
incubation period the methylated DNA was ethanol precipitated and subjected to two 
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more rounds of m.Sssi methylase treatment.  Untreated HMEC DNA was utilized as a 
negative control. 
Bisulfite Modification 
 Bisulfite modification of genomic DNA was carried out using the EZ DNA 
Methylation-Gold kit (Zymo Research, Orange CA).  Briefly, 1 µg of genomic DNA for 
each sample was incubated with a bisulfite mix consisting of hydroquinone, sodium 
bisulfite, and sodium hydroxide.  Bisulfite modification was carried out overnight in a 
thermalcycler with an optimized series of incubation steps necessary for thermal DNA 
denaturation and subsequent sulfonation and cytosine deamination steps.  (10 min at 98 
oC, 150 min at 64 oC, Hold at 4 oC).  Bisulfite modified DNA was aliquoted and archived 
for later use.   
Methyl-Specific PCR (MSP) 
 The methylation status of the promoter regions for five genes was determined by 
the method of MSP further modified as described by House et al (2003) as a nested two-
step approach to increase sensitivity of the reaction.  Primers designed to examine 
methlylation levels at specific sites within genes’ promoter CpG islands are listed in table 
2.2.  Briefly, first round PCR primers flanked the CpG-rich promoter region of the 
respective genes so that they would not discriminate between methylated and non-
methylated nucleotides after bisulfite modification.  PCR products were then diluted 
1:1000 and subjected to the second step of MSP using primers specific to either 
methylated or unmethylated templates.  First round of PCR utilized 1 µl of bisulfite-
treated DNA amplified in a 25 µL reaction mixture containing 1x buffer, 200 nM 
primers, and 0.2 units of HotStar Taq Polymerase (Qiagen, Valencia CA).  First round 
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PCR conditions were as follows: 5 min at 95oC, (30s at 95oC, 30s at 56oC, 30s at 
72oC)x40, 5 min at 72oC.  Second round PCR conditions were similar with the only 
differences being primer annealing at a gene specific temperature and reduction of the 
number of cycles to 25. 
Statistical Analysis 
 Statistical analysis was performed using STATA Data analysis and statistical 
software package (Statcorp LP, College Station TX).  Linear regression models were 
used to analyze the relationship between total and enriched fraction yields with data 
obtained from the questionnaire.  A p-value of p<0.05 was considered statistically 
significant. 
Sample Summary 
 Fifty-four breast milk samples were used for isolation of RNA from the epithelial-
enriched fraction.  Additional samples were then collected to examine the characteristics 
of the cells enriched by magnetic separation.  These included ten samples collected for 
use in a gene expression comparison of the enriched and depleted fractions and eight 
samples collected for flow cytometry analysis.  Preliminary methylation work was 
performed on DNA isolated from four breast milk samples.   Samples isolated after the 
first fifty-four utilized a higher centrifugation speed resulting in higher cellular yields; the 
remainder of the isolation procedure was identical. 
Results 
Sample Processing 
 In 2004 we collected fifty-four breast milk samples.  The purpose of these 
samples was to determine the feasibility of performing the magnetic separation using an 
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epithelial specific antibody and to isolate and collect RNA for downstream gene 
expression analysis.  Cell counts were performed both prior and post separation (Table 
2.3)  Examining both the total and enriched cell counts revealed no significant 
relationship between cellular yields and either age of the donor or age of the infant (Figs 
2.1 & 2.2). 
RNA Isolation 
 Samples were processed as described in the methods and RNA was isolated from 
each epithelial-enriched fraction (Table 2.4).  As highly purified RNA, free of 
contaminants such as DNA and protein, is preferable for accurate downstream 
applications such as gene expression analysis (Bustin 2002) a 260/280 minimum of 1.5 
was selected.  Of the 54 samples processed 16 yielded no recoverable RNA, 18 yielded 
RNA of insufficient purity (260/280 ratio < 1.5), and 20 samples were usable (260/280 
ratio ≥ 1.5).  Acid phenol-chloroform extractions were performed on the samples with 
poor RNA purity in an attempt to remove some of the contaminating protein. 
Unfortunately, acid phenol-chloroform extractions were unsuccessful in further purifying 
the samples and none resulted in quantifiable RNA.       
 Among the samples from which we were able to quantify RNA in the epithelial-
enriched cell fraction, increased cell count was positively correlated with RNA quality 
(Fig 2.3a).  Of the samples from which we were unable to quantify RNA (16 of 54 
samples), 87% contained fewer than a million epithelial cells (X = 5.5x105 cells).  In 
contrast the purest RNA samples (260/280 ≥ 1.5) had a mean enriched cell count of 
approximately 1.7x106. (Fig 2.3b). 
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Preliminary Gene Expression Analysis 
Biomarker Analysis 
 We examined the expression of a panel of genes frequently associated with breast 
cancer onset and/or progression.  Six genes were chosen for this task:  e-cadherin 
(CDH1)(Oka et al. 1993), glutathione-s-transferase pi (GSTPi)(El-Rayes et al. 2003), 
P16INK4a (P16)(Brenner et al. 1996), estrogen receptor α (ER)(Martin et al. 1993), 
target of methylation silencing (TMS-1)(Levine et al. 2003) and breast cancer 1, early 
onset (BRCA1)(Sourvinos et al. 1998).  Examination of expression patterns of these 
genes within 12 breast milk RNA samples which had been successfully purified and were 
available at the time revealed varied expression levels from sample to sample.  
Additionally, GSTPi had reduced expression with respect to age (Fig 2.4a).  The levels of 
the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) varied by only 
4-fold with respect to the highest and lowest sample expression values.  Each gene of 
interest varied considerably more, from a 17-fold difference for BRCA1 to as much as 
970-fold for ER α (Fig 2.4b).   
Luminal Versus Basal Expression 
   Due to depletion of RNA of the first twelve samples the enriched fractions of 8 
breast milk samples which had been isolated since that time (the last usable samples of 
the 54 processed) were tested for the expression of 4 gene markers.  Both p63 (Reis-Filho 
et al. 2002)and cytokeratin 5 (Dairkee et al. 1993) are specific to basal epithelial gene 
expression, and mucin-1(McGuckin et al. 1995) and cytokeratin 18 (Dairkee et al. 1993) 
are specific to luminal epithelial gene expression.  Along with the breast milk samples 
two cell lines, MCF-7 and 184, were used as luminal and basal expression controls 
 15  
 
respectively.  The breast milk samples had very high expression of both mucin-1 and 
cytokeratin 18, both luminal markers.  In contrast they had little to no expression of the 
basal markers.  The cell lines showed their expected expression patterns.  This analysis 
verified that the cells we were looking at expressed largely luminal markers (Fig 2.5).  
Methyl Specific-PCR 
 As a reduction in gene expression can be attributed to DNA hypermethylation, the 
next step was to determine if such epigenetic modifications were also detectable in breast 
milk samples. We screened for the methylation status of a small panel of genes in DNA 
isolated from four breast milk samples which were in addition to the fifty-four used in 
RNA isolations.  Using primers and methods previously described by (House et al. 2003), 
we examined the methylation status of five genes commonly methylated in breast cancer.  
Four of the five (p16, BRCA1, GSTPi, and CDH1) were previously examined in our 
biomarker gene expression study and showed varying levels of expression in the samples 
analyzed.  Performing the analysis on DNA isolated from the four epithelial enriched-
fractions along with the in vitro methylated and non-methylated controls there was no 
visible methylation in the milk samples for the genes and sites analyzed (Fig 2.6).  
However, it was a small number of samples and only one to two CpG sites were analyzed 
per gene.   
FACS Analysis 
Extracellular Staining Experiments Using Cell Lines 
 To determine the efficiency of the column separation and subsequent epithelial 
cell enrichment, two cell lines were mixed at ratios similar to what we have seen in the 
breast milk samples.  A mixture containing 15% MCF-10A (epithelial), and 85% JY 
 16  
 
(lymphoblastoid B-cells) was subjected to the magnetic column separation, and each 
resulting fraction analyzed by dual-colored immunofluorescence by FACS.  The total cell 
fraction contained close to the original percentage of epithelial and lymphoblastoid cells.  
Roughly 77% of the fraction was positive for CD45 and 17% was positive for EpCAM 
expression (Fig 2.7a).  Upon separation, CD45 expression accounted for 96% of the 
depleted cell fraction (Fig 2.7b).  Conversely, the enriched fraction contained 77% 
EpCAM expressing cells.  This population was not pure however with 14% of the 
enriched fraction being composed of CD45 expressing cells (Fig 2.7c).    
Extracellular Staining Using Milk Samples 
 Two breast milk samples were treated and analyzed identically to the cell lines 
(Figs 2.8-2.9).  Comparing the enriched to the depleted fractions, both milk sample 104 
and 116 showed increases in EpCAM expression positivity and a slight decrease in CD45 
expression (Figs 2.8b,c & 2.9b,c)  However neither marker showed as robust expression 
in the milk samples as there was in the cell line study.  A large portion of the cells in each 
fraction of both samples remained unstained.  Considering that the samples were treated 
identically as the samples in the cell line experiment in terms of the fixation and staining 
other factors must have come into play.  One such factor we considered was apoptosis. 
Examination of Apoptosis 
 To determine whether apoptosis was a major factor in the observed flow 
cytometry data, an additional experiment was designed.  Cell fractions from milk sample 
117 were split in half with one portion treated as the other samples were with the dual 
staining of CD45 and EpCAM and the remainder of the sample being dual stained for 
Annexin V and 5’AAD.  Apoptosis is characterized by a number of morphologic 
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features, the earliest of which is disruption of the plasma membrane.  In apoptotic cells, 
the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to 
outer leaflet of the plasma membrane.  Annexin V is a phospholipid-binding protein that 
has high affinity for PS and as such can be used as a measure of cells undergoing the 
early stages of apoptosis.  When used in conjunction with a vital dye such as 7’AAD, 
used to measure cellular necrosis additional information about the health of the cells can 
be obtained. (Vermes et al. 1995). 
 As with the other breast milk samples examined for CD45 and EpCAM 
expression, milk sample 117 had a very large number of unstained cells.  A portion of the 
cells stained positive for CD45 and EpCAM, but there was little to no enrichment of 
epithelial cells when compared to the depleted cell fraction (Figs 2.10b & c).  
Examination of Annexin staining was much more revealing.  A large portion of the cells 
in the total fraction stained positive for Annexin-V PE (Fig 2.11a).  The comparison 
between the depleted and enriched cell fractions revealed that 30% of the depleted cells 
stained positive for Annexin-V while the enriched fraction had nearly 80% positive 
staining (Fig 2.11b & c).  Unfortunately 7’AAD staining was ineffective however a 
simple propidium iodide staining showed that 29% of the cells in the total fraction were 
necrotic or had already undergone cell death (Fig 2.11d). 
Cell Line Studies Using Intracellular Staining 
 
 To determine if intracellular markers would be affected by apoptosis to the same 
extent as surface antigens, such as EpCAM, intracellular cytokeratin (CK) staining was 
utilized.  Analysis of CK staining on MCF-10A cells indicated very high reactivity with 
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nearly 100% of the cells showing the expected CK expression (Fig 2.12b) as compared to 
the unstained cells (Fig 2.12a). 
Milk Sample Studies Using Intracellular Staining 
 With the success of the CK staining on cell lines the same protocol was followed 
on three breast milk samples (Figs 2.13-2.15). Two of the three samples showed a 
marked increase in the staining of the epithelial fraction and a slight decrease of staining 
in the depleted fraction (Figs 2.13b,c & 2.15b,c).  Whereas using EpCAM extracellular 
staining only 5-20% of the enriched cells stained positive, CK staining was much more 
robust topping out at nearly 50% positivity for one of the samples (Fig 2.15c).  Even so 
there was quite a bit of variability and one of the samples did not show any substantial 
difference between the enriched and depleted fractions (Fig 2.14b & c).   
Enriched Fraction Versus Depleted Fraction Expression 
 Although the flow cytometry data answers much about the quality of the cell 
separation and the condition of the cells a number of questions still remain.   Since the 
cells were observed to be undergoing apoptosis we were uncertain if the FACS analysis 
results were truly representative of the cell populations within each cell fraction from 
breast milk.  Alternatively, the purity may have been higher, but due to inefficient 
binding of the antibodies we were unable to see it.  For this reason we attempted to 
further ascertain the purity of the separation of breast milk samples by turning to 
additional RNA isolations and subsequent gene expression analysis.  RNA was isolated 
from both the depleted and enriched breast milk cell fractions after magnetic cell 
separation.    Two markers, Mucin-1 (MUC1)(epithelial specific) and leukocyte common 
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antigen (CD45)(leukocyte specific), were selected examine how gene expression of the 
enriched fraction compared to the depleted within the same sample.   
 In the 6 samples examined, the enriched fraction showed higher expression of the 
MUC1 epithelial marker than the depleted fraction (Fig 2.16a). With the exception of one 
sample the depleted fraction expressed much higher levels of CD45 (Fig 2.16b).The 
enriched fraction of sample 120 expressed high levels of both MUC1 and CD45.  This 
unexpected outcome could have resulted from the observation that the paramagnetic 
column clogged during the separation procedure which consequently did not effectively 
enrich for epithelial cells in the sample.  The expression level of each marker varied 
greatly (Table 2.5).  This data does serve to strengthen the argument that in performing 
the MACS procedure there is a higher percentage of epithelial cells in the enriched 
fraction than in the depleted. 
Discussion 
 The initial work on this project tested the feasibility of obtaining cells from breast 
milk by magnetic cell separation and using these cells in downstream applications such as 
quantitative gene expression and methylation analysis.  
 Isolation of RNA from the first fifty-four samples proved to be a difficult task.  
Although tri-reagent had been used on multiple occasions to isolate highly pure RNA 
from cell line samples, more often than not RNA isolated from the enriched breast milk 
cells using the same technique proved to be of much lower purity.  52% or 20 of the 38 
sucessful isolations resulted in acceptably pure RNA (A260/A280 ≥ 1.5).  The most 
likely reason is carryover of excess proteinacious material from the breast milk itself 
(Bergqvist et al. 1989).  Under normal circumstances cleanup of this protein is routine 
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with acid-phenol extractions.  Unfortunately the methods used were unsuccessful in 
recovering quantifiable RNA.  Samples from which the purest RNA was isolated from 
had a higher mean enriched cell count than samples that resulted in low purity, or no 
quantifiable RNA.  This result could possibly be indicative of a limitation of the Tri-
reagent isolation technique on cells from breast milk.  Attempts were made on three 
occasions to use Qiagens’ RNeasy silica column based RNA isolation method as an 
alternative.  However, none of the isolation attempts resulted in quantifiable yields 
although RNA simultaneously isolated from cell lines did.  Since this pilot study new 
kits, such as the Absolutely RNA® Nanoprep Kit (Stratagene, Santa Clara CA) have 
come on the market which are specialized for isolation of RNA for use in qRT RT-PCR 
from very small samples.  In the case of the Nanoprep kit, they suggest that it is possible 
to isolate usable RNA from a single cell and may be a worthwhile avenue to pursue in the 
future if additional gene expression work is desired. 
 The twenty usable RNA samples were utilized in two gene expression screening 
experiments.   The first experiment examined expression of a panel of breast cancer 
related genes and found that the samples exhibited varying levels of expression, with a 
possible trend showing decreased GSTPi expression with respect to donor age.   The 
second experiment verified that the cells being enriched expressed the luminal markers 
cytokeratin 18 and mucin-1.  As decreases in gene expression can be attributed to DNA 
hypermethylation (Baylin et al. 2005) we chose to examine the methylation status of 
some of these genes in DNA isolated from the epithelial-enriched fraction. 
   In methylation analysis genomic DNA is subjected to the process of bisulfite 
modification during which non-methylated cytosine residues are chemically modified and 
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converted to uracil.  Methylated cytosines on the other hand are unable to undergo this 
reaction and remain as cytosine (Wang et al. 1980).   In this way it is possible to 
discriminate between methylated and non-methylated nucleotides.  In their paper, 
Herman et al (1996) described the use of primers specific to either methylated or non-
methylated DNA templates.  By performing PCR and subsequent gel electrophoresis on 
the resulting products it is possible to determine if specific sites within the promoter 
region are methylated.   Methyl-specific PCR (MSP) was performed on four enriched-
epithelial DNA samples however methylation was not detected in the five genes 
examined.  This did not come as a surprise as MSP assays only for sites encompassed by 
the discriminating primer sets which in the case of the genes examined were no more 
than one to two sites per gene.  Also, although sensitive MSP relies on examination of 
PCR products  and as such is much more of a qualitative than quantitative measure of 
DNA methylation levels (Herman et al. 1996).  Upon seeing these results we determined 
that a more quantitative approach was necessary and settled upon the method of 
Pyrosequencing which will be discussed in detail in chapter 3.   
 Although the preliminary gene expression work had shown luminal epithelial 
expression from RNA isolated from the enriched fraction cells it did not answer questions 
concerning the efficiency of the cell separation.  In order to address that issue we turned 
to flow cytometry experiments.  Dual staining with EpCAM, the same marker used for 
MACS selection, and CD45, a leukocyte marker, showed a high degree of epithelial cell 
enrichment in the cell line mixing experiment.  However, when milk samples were 
treated in the same fashion, a large population of cells remained unstained.  Although 
there was an increase in EpCAM expression between the enriched and depleted fraction, 
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it was not same efficiency as the cell line study.  We surmised that one possible 
explanation could be that the cells were undergoing apoptosis.  
 Staining for Annexin-V revealed that although cells in the pre-separated and post-
separated cell fractions were undergoing apoptosis the largest percentage of apoptotic 
cells were identified within the enriched fraction.  This was an important finding.  During 
the process of apoptosis a number of changes occur affecting the morphology of the 
dying cell.  The hallmarks of this process are cellular shrinkage, membrane blebbing, 
nuclear condensation and finally cellular fragmentation.  As the cell advances through the 
cascade of events, cell surface characteristics, such as the location and existence of many 
protein markers, change (Vermes et al. 2000).  Additionally, endogenous endonucleases 
become activated which begin to degrade RNA and DNA which can also escape from the 
cell through the leaky membrane (Arends et al. 1990).  The process of apoptosis 
answered two questions.  The first of which was why RNA yields from the enriched 
fraction were considerably lower than the yields from a similar number of cultured 
mammalian cells.  Typically a million cells would provide more than adequate RNA from 
any cell line, but to obtain a similar yield would require two to four times as many 
enriched fraction cells.  The second question answered was why so many cells remained 
unstained in the FACS analysis.  If cell surface antigenicity were being affected by the 
process of apoptosis, then the ability of our fluorescent antibody to bind could possibly 
be hindered.  This was an interesting, yet problematic revelation.  The question then 
became, if antibody binding was being affected, could flow cytometry yield meaningful 
results?  Also, and more importantly, has this been affecting the efficiency of the MACS 
cell separation which also utilizes an antibody specific to a cell surface marker? 
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 To address these questions we turned to using an intracellular stain for 
cytokeratins.  The purpose was two-fold.  First, it would allow us to use a marker other 
than the one used for cell separation in case it had been saturated by the magnetic 
antibody.  Second, if apoptosis was affecting cellular markers we hoped that using a pan-
cytokeratin antibody (7, 8, 18, and 19) would increase our chances of detecting epithelial 
cells in the enriched fraction.  Intracellular staining for cytokeratin revealed a higher 
percentage of epithelial cells in the enriched fraction, but the level of detection still varied 
widely from sample to sample.   
 In the event that apoptosis was still affecting the assay results we chose to 
perform a side by side gene expression comparison of the enriched and depleted 
fractions.  Every enriched fraction showed a higher level of epithelial marker gene 
expression than in the depleted fraction.  However, the level of expression varied from 
sample to sample. 
 From the both the FACS and gene expression data collected, we have been able to 
determine that the enriched fraction contains a higher percentage of epithelial cells than 
the depleted fraction.  The degree of enrichment varies widely from sample to sample 
which would lead to the conclusion that the effects of apoptosis on antibody binding 
extend beyond the immunofluorescence work and is having an effect on the magnetic 
separation itself.  One major concern is that if the enriched fraction isn’t pure, detection 
of epithelial-biomarkers of breast cancer might be masked by the other cells within the 
fraction.  As high levels of promoter hypermethylation are frequently found in cancer 
(Paz et al. 2003) one way to determine whether this is the case would be to examine 
promoter hypermethylation in cancerous patients and determine if these high levels are 
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still detectable.  In the meanwhile we have chosen to focus on the obtaining a larger pool 
of breast milk samples, performing quantitative methylation analysis, and determining if 
the methylation status of these samples in a panel of genes can be correlated to known 
breast cancer risk factors such as age. 
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Table 2.1 Quantitative Real-Time RT-PCR primers for use in gene expression 
analysis.   
Primers were designed in Primer 3 with the exception of ER-α which was taken from 
Fasco et al. 2003. 
 
       
Gene Genbank Start Stop 
Predicted 
Size 
Acquiri
ng 
Temp Primer (5'-3', Forward, Reverse) 
  
Accession 
ID     (bp) (°C)   
CK5 NM_00424 117 343 226 80 CAACCCACTAGTGCCTGGTT 
      ATAGCCACCCACTCCACAAG 
CK18 NM_000224 919 1082 163 82 CACAGTCTGCTGAGGTTGGA 
      GAGCTGCTCCATCTGTAGGG 
Mucin-1 NM_002456 774 897 123 80 GTGCCCCCTAGCAGTACCG 
      GACGTGCCCCTACAAGTTGG 
HPRT  NM_000194 587 834 247 77 ACCCCACGAAGTGTTGGATA 
      AAGCAGATGGCCACAGAACT 
CDH1 NM_004360 610 810 200 80 TGCCCAGAAAATGAAAAAGG 
      GTGTATGTGGCAATGCGTTC 
P63 NM_003722 745 971 226 79 TCCTCAGGGAGCTGTTATCC 
      CTGGGGTGGCTCATAAGGTA 
BRCA1 NM_007306 6243 6469 226 77 TAGGGCTGGAAGCACAGAGT 
      AATTTCCTCCCCAATGTTCC 
GSTPi NM_000852 324 530 206 82 ACCTCCGCTGCAAATACATC 
      GGCTAGGACCTCATGGATCA 
P16ink4a NM_058197 1127 1365 238 78 CCCACTACCGTAAATGTCCA 
      TCAAGAGAAGCCAGTAACCC 
TMS-1 AF184072 575 727 152 84 AATTCTGGCTCCCCTAGGAA 
      AAAAGGCAGAGAGTGCAAA 
ER-α NM_000125 1302 1506 204 80 ATGATCAACTGGGCGAAGAG 
      GATCTCCACCATGCCCTCTA 
CD45 NM_080921 3323 3528 205 80 GGTTTCCACATTCGAGCAAT 
      TTCAGCCTGTTCCTTTGCTT 
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Table 2.2 Primers utilized for Methyl-Specific PCR analysis.  From House et al. 
2003. 
 
Gene Primer Type Primer (5'-3', Forward, Reverse) Size 
   
 
p16INK4A External 5'-AGAAAGAGGAGGGGTTGGTTGG-3' 193 
  5'-ACRCCCRCACCTCCTCTACC-3'  
 Internal Methylated 5'-TTATTAGAGGGTGGGGCGGATCGC-3' 150 
  5'-GACCCCGAACCGCGACCGTAA-3'  
 Internal Unmethylated 5'-TTATTAGAGGGTGGGGTGGATTGT-3' 151 
  5'-CAACCCCAAACCACAACCATAA-3'  
BRCA-1 External 5'-GAGAGGTTGTTGTTTAGYGGTAGTTTT-3' 143 
  5'-TCTAAAAAACCCCACAACCTATCC-3'  
 Internal Methylated 5'-TCGTGGTAACGGAAAAGCGC-3' 75 
  5'-AAATCTCAACGAACTCACGCCG-3'  
 Internal Unmethylated 5'-TTGGTTTTTGTGGTAATGGAAAAGTGT-3' 86 
  5'-CAAAAAATCTCAACAAACTCACACCA-3'  
CDH1 External 5'-GTGTTTTYGGGGTTTATTTGGTTGT-3' 186 
  5'-TACRACTCCAAAAACCCATAACTAACC-3'  
 Internal Methylated 5'-TGTAGTTACGTATTTATTTTTAGTGGCGTC-3' 112 
  5'-CGAATACGATCGAATCGAACCG-3'  
 Internal Unmethylated 5'-
TGGTTGTAGTTATGTATTTATTTTTAGTGGTGTT-3' 
120 
  5'-ACACCAAATACAATCAAATCAAACCAAA-3'  
GSTPi External 5'-GGGATTTTAGGGYGTTTTTTTG-3' 159 
  5'-ACCTCCRAACCTTATAAAAATAATCCC-3'  
 Internal Methylated 5'-TTCGGGGTGTAGCGGTCGTC-3' 91 
  5'-GCCCCAATACTAAATCACGACG-3'  
 Internal Unmethylated 5'-GATGTTTGGGGTGTAGTGGTTGTT-3' 97 
  5'-CCACCCCAATACTAAATCACAACA-3'  
APC External 5'-TGGGYGGGGTTTTGTGTTTTATT-3' 136 
 
 5'-TACRCCCACACCCAACCAATC-3'  
 
Internal Methylated 5'-TATTGCGGAGTGCGGGTC-3' 98 
 
 5'-TCGACGAACTCCCGACGA-3'  
 
Internal Unmethylated 5'-GTGTTTTATTGTGGAGTGTGGGTT-3' 108 
  5'-CCAATCAACAAACTCCCAACAA-3'  
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Table 2.3 Cell counts of total and epithelial-enriched fractions and donor 
demographics of 54 breast milk samples collected in 2004.  
(*)Total cell counts were made on 34 of the 54 breast milk samples.  (**)One sample 
arrived frozen (saved for 3+ months in a cycling freezer) from a breast cancer patient and 
resulted in no cellular or RNA yields. 
 
 
 Cell Separation Information 
    
 
Mean Std Dev N 
Total Cells 5,702,767 6,173,545 *34 
Total Cells per mL 92,169 100,683 *34 
Enriched Cells 1,077,143 876,860 **53 
Enriched Cells per mL 17,945 16,484 **53 
Volume (mL) 70 33 54 
    
 
Donor Demographics 
    
 
Mean Std Dev N 
Donor Age (Years) 37 5 54 
Babys Age (Days) 188 142 54 
Live Births 1.54 0.73 54 
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Table 2.4 Total µg of RNA for each of the first 54 breast milk samples and their 
respective 260/280 absorbance ratios.   
Of the 54 samples processed 16 yielded no recoverable RNA, 18 yielded RNA of 
insufficient quality (260/280 ratio < 1.5), and 20 samples were usable (260/280 ratio ≥ 
1.5). 
 
Sample # 
Total µg 
RNA 
260/280 
Ratio 
 
Sample # 
Total µg 
RNA 
260/280 
Ratio 
1 4.02 1.48  31 1.92 1.59 
2 1.26 1.49  32 3.58 1.42 
3 3.98 1.51  33 2.46 1.58 
4 0.00 0.00  34 1.26 1.78 
5 0.00 0.00  35 2.34 1.51 
6 0.00 0.00  36 3.21 1.90 
7 3.48 1.91  37 2.81 1.66 
8 8.30 1.35  38 0.79 1.62 
9 1.76 1.22  39 0.60 1.71 
10 0.00 0.00  40 1.05 1.85 
11 3.18 1.40  41 1.43 1.34 
12 2.20 1.53  42 0.62 1.41 
13 2.70 1.43  43 0.00 0.00 
14 2.54 1.41  44 0.00 0.00 
15 0.00 0.00  45 0.90 1.92 
16 0.00 0.00  46 0.00 0.00 
17 2.22 1.41  47 0.00 0.00 
18 3.10 1.47  48 2.10 1.19 
19 2.42 1.43  49 2.26 1.26 
20 0.00 0.00  50 1.44 1.18 
21 2.90 1.61  51 1.85 1.26 
22 6.02 1.96  52 0.00 0.00 
23 7.64 1.97  53 0.00 0.00 
24 1.88 1.48  54 0.00 0.00 
25 0.00 0.00     
26 2.84 1.85     
27 3.16 1.68    = No RNA quantifiable 
28 0.00 0.00    = RNA below 1.50 threshold 
29 4.96 1.81    = Good usable RNA sample 
30 2.54 1.57     
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Table 2.5 Calculated positive fold change of the epithelial-enriched (+, green) versus 
depleted cell fractions (-, red).   
For example, the depleted fraction of sample 126 expresses 35.1 fold higher levels of 
CD45 than the enriched fraction.  The enriched cells from the same sample express 5.5 
fold higher expression of MUC1 than the depleted fraction. 
 
 
126  
(+) 
126 
(-) 
127 
(+) 
127 
(-) 
128 
(+) 
128 
(-) 
129 
(+) 
129 
(-) 
117 
(+) 
117 
(-) 
120 
(+) 
120 
(-) 
CD45 
(Leukocyte) - 35.14 - 17.67 - 5.58 - 4.63 - 5.41 24.43 - 
MUC1 
(Epithelial) 5.51 - 3.08 - 2.89 - 1.39 - 2.97 - 5.44 - 
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Figure 2.1 Relationship between total cell count per mL of breast milk and (a) the 
donor’s age and (b) nursing length.   
Shaded area represents the 95% confidence interval. 
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Figure 2.2 Relationship between enriched cell count per mL of breast milk and (a) 
the donor’s age and (b) nursing length.   
Shaded area represents the 95% confidence interval. 
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Figure 2.3 Relationship between cell yield and RNA purity.  
The ratio of absorbance at 260nm and 280 nm is used to assess the purity of RNA and a 
lower ratio can indicate the presence of protein contamination. a) Epithelial-enriched cell 
yield and RNA purity (260/280 ratio) for samples from which RNA was successfully 
purified (n=38).  b) Box and whisker plots of RNA purity (260/280 ratio) with respect to 
total enriched cells for all samples (n=54).  Boxes include 50% of all observations and 
median (horizontal line).  Box hinges indicate the 25th and 75th percentiles.  Whiskers 
indicate minimum and maximum values when no outliers are present. 
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Figure 2.4 Expression of a panel of genes frequently hypermethylated and silenced 
in breast cancer.  
RNA was isolated from the epithelial-enriched cell fraction from breast milk and real 
time RT-PCR was performed as described in the methods.  Twelve breast milk samples 
from donors of varied ages were analyzed in duplicate for each gene of interest and then 
normalized against the housekeeping gene, HPRT, which was also analyzed in duplicate.  
The resulting relative gene expression values were plotted against donor age and linear 
regressions performed to determine the relationship if any between gene expression and 
age. 
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Figure 2.5 Expression of luminal and basal cell markers in the epithelial-enriched 
cell fraction of breast milk.   
Real time RT-PCR was performed as described in the methods.  Samples were run once 
and normalized to HPRT, which was run in duplicate.  MCF-7 and 184 cell line RNA are 
included as controls for (a) luminal and (b) basal expression respectively. 
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Figure 2.6 Methyl-Specific PCR results for five genes commonly found to be 
methylated in cancer.   
Analysis was performed on DNA isolated from the epithelial-enriched fraction of four 
breast milk samples.  In vitro methylated HMEC DNA (as described in the methods) as 
well as non-treated HMEC DNA were used as positive and negative controls 
respectively. 
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Figure 2.7 Flow cytometry analysis of mixing experiment of MCF-10A (epithelial) 
and Jurkat (T-lymphocyte) cells separated by magnetic antibody cell separation.  
To simulate the  cell fraction conditions found in breast milk samples Jurkat cells 
(lymphocyte) made up 87.5% of the total cell fraction, and the MCF-10A (epithelial) 
cells made up the remaining 12.5%.  Cell separation was performed using the magnetic 
separation protocol.  All three fractions, (a) total, (b) epithelial depleted (negative), and 
(c) epithelial enriched (positive), were dual stained with anti-CD45 and anti-EpCAM 
fluorescent antibodies Although there was significant enrichment of EpCAM positive 
MCF-10A cells in the positive fraction (green), there was also a small amount of non-
EpCAM expressing cells carried-over (red). 
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Figure 2.8 Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 104 cell fractions.  
(a) unseparated total cell fraction, (b) depleted (negative) fraction, (c) enriched (positive) 
fraction.  Examination of the epithelial depleted fraction (b) shows fewer EpCAM stained 
cells than the epithelial enriched fraction.  There is a large portion of cells which remain 
unstained in all cell fractions which could be due to loss of antigenicity from cells 
undergoing apoptosis. 
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Figure 2.9 Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 116 cell fractions.  
(a) unseparated total cell fraction, (b) depleted (negative) fraction, (c) enriched (positive) 
fraction.  This milk sample exhibited a similar separation profile to milk sample 104 in 
figure 2.8.  There is an increase in the percentage of EpCAM positive cells in the 
epithelial enriched fraction, however there is a large number of unstained cells in all cell 
fractions.    
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Figure 2.10 Flow cytometry analysis of EpCAM / CD45 dual staining of breast milk 
sample 117 cell fractions.  
(a) unseparated total cell fraction, (b) depleted (negative) fraction, (c) enriched (positive) 
fraction.  This sample exhibited high CD45 lymphocytic staining, but did not show any 
significant increase in EpCAM stained cells.  More than ¾ of each fraction does not stain 
for either marker. 
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Figure 2.11 Flow cytometry analysis of Annexin-V apoptotic staining of milk sample 
117.   
The large percentage of unstained cells in each cellular fraction were postulated to be due 
to loss of antigen presentation due to the cells undergoing apoptosis. All fractions showed 
high levels of Annexin-V staining indicating cells undergoing early apoptosis.  One 
interesting observation was that the positive fraction (c) exhibited a 2-fold increase in 
apoptotic cells over the epithelial depleted fraction (b) illustrating another distinction 
between the two cell populations.  Propidium iodide staining was also performed on the 
total fraction showing that about a 3rd of the cell population had transitioned into late 
apoptosis and necrosis.  These observations help to explain the large population of 
unstained cells in the earlier CD45/EpCAM extracellular staining experiments.  
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Figure 2.12 Flow cytometry analysis of intracellular cytokeratins 7, 8, 18 and 19 in 
MCF-10A cells permeabilized with .5% tween 20.   
With evidence of cellular apoptosis occurring in the cells isolated from breast milk an 
intracellular staining experiment was designed to see if such a marker would affected to 
less of a degree than the extracellular EpCAM/CD45.  A) unstained MCF-10A cells B) 
cytokeratin stained MCF-10A.   
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Figure 2.13 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk sample 126 fractions.  
(a) unseparated total cell fraction, (b) depleted (negative) fraction.  Comparing the 
epithelial enriched fraction (c) to the epithelial depleted fraction (b) there is a significant 
increase in cytokeratin stained cells in the enriched fraction compared to earlier 
extracellular EpCAM staining.   
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Figure 2.14 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk sample 127 fractions. 
 (a) unseparated total cell fraction, (b) depleted (negative) fraction.  A large portion of the 
cells within this sample remained unstained, and there appeared to be no significant 
difference between the positive and negative fractions from this sample.   
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Figure 2.15 Flow cytometry analysis of intracellular cytokeratin staining of breast 
milk 129 fractions.  
(a) unseparated total cell fraction, (b) depleted (negative) fraction.  Comparing the 
epithelial enriched fraction (c) to the epithelial depleted fraction (b) there is a significant 
increase in cytokeratin stained cells in the enriched fraction compared to earlier 
extracellular EpCAM staining.   
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Figure 2.16 Gene expression comparison of a) MUC-1 and b) CD45 expression in 
both the enriched (+) and depleted (-) cell fractions magnetically separated from six 
breast milk samples.   
Each sample was PCR’d once and normalized to the housekeeping gene HPRT.  For the 
majority of the samples MUC-1 epithelial marker expression was higher in the epithelial 
enriched fraction and the CD45 lymphocyte marker was higher in the epithelial depleted 
fraction. 
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Chapter 3:  Examination of Promotor Hypermethylation Patterns in Enriched 
Exfoliated Epithelial Cells in Breast Milk by Pyrosequencing 
 
Introduction 
 We had previously described the use of methyl-specific PCR to analyze a small 
set of breast milk samples for promoter DNA hypermethylation.  This qualitative 
technique had been used for years as one of the most widely accepted means of 
methylation assessment (Shames et al. 2007).  However, recent technological advances 
have resulted in numerous highly quantitative and sensitive alternative approaches to 
methylation study.  The methodology we chose to explore in further detail is that of 
quantitative pyrosequencing.   
 Pyrosequencing was developed as an alternative to dideoxy sequencing and is 
based on the detection of pyrophosphate (PPi) (Nyren 2007).  Nucleotides are dispensed 
in a specific order determined by the template sequence.  As a nucleotide gets 
incorporated by the DNA polymerase during strand elongation, PPi molecules are 
released.  Free PPi molecules are converted to ATP by ATP sulfurylase, which provides 
energy to luciferase to oxidize luciferin and generate light.  This light signal is directly 
proportional to the amount of nucleotide incorporated allowing for quantitative 
assessment.  The reaction is then reset by the action of an apyrase enzyme which digests 
excess nucleotides. 
 There are numerous advantages to Pyrosequencing technology over MSP.   One 
major advantage is that Pyrosequencing is a sequenced based method of analysis, which 
allows for much more specific data than can be acquired through MSP.  Rather than just 
looking at a band on a gel and determining whether a small region is methylated or not, 
by examining a Pyrosequencing readout it is possible to determine which specific CpG 
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sites are methylated and to what degree (Shames et al. 2007).  Additionally, 
Pyrosequencing can detect partially methylated sequences that are outside of the priming 
sites, whereas MSP can only detect sequences that are completely complimentary to the 
primer sequences (Tost et al. 2007).  While MSP allows for the examination of only one 
to two CpG sites, it is possible to examine upwards of 15 sites across the promoter of the 
gene of interest through pyrosequencing.  Moreover this technique is highly sensitive 
with Shuji Ogino, Dana Farber Cancer Institute, reporting accurate detection of as low as 
5% methylation. (Liying Yan, EpigenDx, personal communication)   
 We proposed to use quantitative pyrosequencing to examine promoter 
hypermethylation of a panel of genes in DNA isolated from the enriched-epithelial 
fraction of roughly one hundred breast milk samples.  Furthermore we propose that the 
methylation status of these gene promoters will correlate to donor age, a major risk factor 
in breast cancer (Singletary 2003).   
 In addition to examining age-related relationships with DNA hypermethylation 
we hypothesized that the protective effects of pregnancy and lactation could be attributed 
to a reduction in DNA hypermethylation as a result of either early pregnancy or parity.  
The reduction in breast cancer risk conveyed by both pregnancy and lactation has been 
well documented.  Women who give birth before age 25 exhibit a decrease in their 
lifetime risk of developing breast cancer which continues to decrease with subsequent 
pregnancies (MacMahon et al. 1970; Lambe et al. 1996).  Additionally, lactation has been 
associated with a 20% reduction in breast cancer risk and is further reduced by length of 
nursing (Newcomb 1997).  Although both direct physical effects and hormonal changes 
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have been purported as the protective mechanism attributed to pregnancy and lactation 
we explored a reduction in DNA methylation as another possible mechanism. 
  Six genes which included RASSF1A, TMS-1, CDH1, SFRP1, GSTPi, and 
CRBP1 were chosen for analysis due to their respective roles in breast cancer and for 
previous studies showing age associated trends (Ahuja et al. 1998; Kwabi-Addo et al. 
2007; Euhus et al. 2008). 
 Rass association domain family 1 protein (RASSF1A) is a tumor suppressor 
which has been implicated in the development of many human cancers including breast 
(Donninger et al. 2007).  Over expression of this gene promotes apoptosis, cell cycle 
arrest and reduces the tumorigenicity of cancer cell lines (Agathanggelou et al. 2005).  
Aberrant promoter methylation of RASSF1A has been frequently detected in several 
tumor types including breast and has even been detected in serum of breast cancer 
patients (Shukla et al. 2006).  Additionally fine needle aspiration (FNA) of benign breast 
samples from 70% of unaffected women at high risk for breast cancer (Gail risk index >2) 
had methylated RASSF1A promoters compared with only 29% from women at low or 
intermediate risk (Euhus et al. 2007).  Although age-related trends have not been 
examined in normal breast tissue, a high correlation between age and RASSF1A 
methylation has been found in prostate tissue (Kwabi-Addo et al. 2007).   
 Cellular retinol-binding protein 1(CRBP1) functions in retinol storage.  Vitamin 
A is required for the differentiated state of adult epithelium which includes attributes 
such as cell-cell and cell-matrix junctions (Farias et al. 2005).  CRBP1 is uniformly 
expressed in normal breast epithelium but down-regulated in approximately 24% of 
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human breast cancers (Kuppumbatti et al. 2000).  This down-regulation has been linked 
to DNA hypermethylation in many tissues including breast (Arapshian et al. 2004).  
 Target of methylation silencing 1 (TMS-1) has roles in the regulation of 
apoptosis, activation of inflammatory caspases and the regulation of NF-κB activity 
(Srinivasula et al. 2002).  TMS-1 expression has been found to be down-regulated in 40% 
of primary breast tumors due to hypermethylation.  Additionally this gene has been 
shown to suppress the growth of breast cancer cells implying a possible tumor suppressor 
role (Conway et al. 2000).   
 Secreted frizzle related protein 1 (SFRP1) is a tumor suppressor gene encoding a 
WNT signaling antagonist abundantly expressed in normal breast tissue and is found to 
be frequently lost and hypermethylated in breast cancer (>70%) (Veeck et al. 2006).  
Activation of the WNT signaling pathway leads to an increase in levels of the 
transcription factor β-catenin which in turn activates a number of downstream genes 
involved in cell growth, survival, intercellular adhesion and cellular morphogenesis (Ilyas 
2005).   
 E-Cadherin (CDH1) has functions in maintaining cell-cell adhesions in epithelial 
tissues.  In normal adult breast tissue its expression is found typically in luminal 
epithelial cells (Rasbridge et al. 1993).   In breast cancer, loss of E-cadherin expression 
correlates with loss of differentiation, increased invasiveness and tumor grade, metastasis 
and poor prognosis (Berx et al. 2001).  E-Cadherin has also been found to be 
hypermethylated in cancerous breast tissue (Caldeira et al. 2006). 
 Glutathione-s-transferase pi  (GSTPi) plays a role in protecting cells from 
cytotoxic and carcinogenic agents (Su et al. 2003).  Expression of GSTPi varies from 
 50  
 
tissue to tissue, however loss of GSTPi expression has been attributed to DNA 
hypermethylation (Zhang et al. 2005).  This methylation has been detected in fine needle 
washings from breast lesions (Jeronimo et al. 2003) and has been correlated to age in 
prostate (Kwabi-Addo et al. 2007). 
Materials and Methods 
Acquisition of Donor Samples 
 One hundred and eleven nursing donors were asked to provide a milk sample of 
approximately 100 mL and to complete a comprehensive personal information and 
lifestyle questionnaire.  Human subject use, which included informed consent, was 
approved by the University of Massachusetts, IRB Human Research Protection Office 
(HRPO).   
 Milk Sample Processing 
 Milk samples were collected within an hour of expressing and processed 
immediately upon arrival at the lab.  The volume of the sample was first recorded and the 
sample was then diluted 1:1 in sterile PBS to reduce viscosity of the milk.  The total cells 
in the sample were pelleted at 1000 G for 10 minutes.  The supernatant from this initial 
spin, including all of the milk fat, was manually transferred into an acid washed 
collection bottle and archived (-80oC) for later chemical extraction.  The cell pellet was 
then resuspended in a large volume of PBS.  Repeated washing and centrifugation steps 
were performed (between 3-5 repetitions depending on sample viscosity) were performed 
to remove as much milk as possible. The washed cell pellet was then resuspended in 1 
mL of degassed 2 mM EDTA/.5% BSA in PBS.  A small aliquot of the resuspended cells 
was used to determine total cells in the sample by hemocytometer counts. 
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Magnetic Antibody Cell Separation (MACS) 
 The cell suspension was centrifuged for 10 minutes at 210 G to pellet cells.  For 
less than 1x107 cells, the pellet was resuspended in 60 µl of degassed 2 mM EDTA/.5% 
BSA in PBS, with 20 µl of epithelial-specific direct MACS HEA-125 microbeads 
(Miltenyi Biotec, Germany) and 20 µl of Fc blocking reagent (Miltenyi Biotec, 
Germany).  Volumes were scaled up for larger numbers of cells. The resulting cell-
microbead suspension was incubated for 15 minutes at 4ºC.  After the incubation step, the 
total volume was brought up to 1 mL of degassed 2 mM EDTA/.5% BSA in PBS and the 
suspension was again centrifuged at 210 G for 10 minutes to pellet the cells.  The 
supernatant was decanted and the pellet was resuspended in 0.5 mL of degassed PBS.  
Cell separation using the MACS paramagnetic column & stand (Miltenyi Biotec, 
Germany) was performed as indicated in the manufacturer’s protocol resulting in 
isolation of both epithelial-depleted (negative) and epithelial-enriched (positive) 
populations.  The cells in the resulting positive fraction, mixed 1:1 with trypan blue, were 
again counted using a hemocytometer to ascertain the number of enriched exfoliated 
breast epithelial cells.  Both the positive and negative fractions were pelleted at 210 G for 
10 minutes to be utilized in downstream applications.  
DNA Isolation 
 Total genomic DNA was isolated from both the enriched and depleted fractions 
using the QIAamp DNA isolation kit (Qiagen, Valencia CA) with the addition of RNAse 
A and Proteinase K digestion steps as per manufacturer’s suggestions.  DNA was 
quantified and assayed for quality using a Genequant (Amersham Biosciences, 
Buckinghamshire UK). 
 52  
 
Bisulfite Modification of DNA 
 Bisulfite modification of genomic DNA was carried out using the Epitect 
Bisulfite Kit (Qiagen, Valencia CA).  Briefly, 1 µg of genomic DNA for each sample was 
incubated with a bisulfite mix consisting of hydroquinone, sodium bisulfite, and sodium 
hydroxide.  Bisulfite modification was carried out overnight in a thermalcycler with an 
optimized series of incubation steps necessary for thermal DNA denaturation and 
subsequent sulfonation and cytosine deamination steps.  (5 min at 99oC, 25 min at 60 oC, 
5 min at 99 oC, 85 min at 60 oC, 5 min at 99 oC, 175 min at 60 oC, Hold at 20 oC).  
Bisulfite modified DNA was aliquoted and archived for later use.  Methylated and 
unmethylated controls for analysis were created using CpGenome universally 
unmethylated DNA (Chemicon, Temicula CA).  Briefly, 5 ug of unmethylated was 
treated with one unit of CpG methyltransferase (SssI) (New England Biolabs,) @ 
37C for one hour followed by 20 minutes of inactivation at 65C.  The DNA was then 
ethanol precipitated and retreated with CpG methylase for two subsequent rounds to 
ensure complete conversion. 
Pyrosequencing Primers 
 All primers used in this portion of the study are listed in Table 3.1.  Primer sets 
for three of the six genes of interest RASSF1A, GSTPi, and CDH1 were already available 
through Biotages’ Pyromark Assay Database (http://techsupport.pyrosequencing.com/).  
For each remaining gene biotinylated primers were designed for the CpG island region 
flanking the transcription start site at the 5’UTR with the assistance of EpigenDx and 
their Pyrosequencing assay design software.  Each designed primer set underwent PCR 
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bias testing using a mixing experiment utilizing in vitro methylated and non-methylated 
DNA (Figs 3.1-3.3) 
PCR Amplification for Pyrosequencing Analysis 
 Bisulfite-pyrosequencing was used to assess for methylation of 6 genes of interest 
(TMS-1, SFRP1, RASSF1A, CRBP1, GSTPi, and CDH1).  1 µl of bisulfite-modified 
DNA was amplified in 30 µL of reaction mixture containing 1x buffer, 200 nM primers, 
and 0.2 units of HotStar Taq Polymerase (Qiagen, Valencia CA).  Each PCR product was 
amplified over 45 cycles at an annealing temperature unique to each primer set (Table 
3.1).  Included with each round of sequencing were a series of controls.  In addition to the 
m.Sssi methylated HMEC and non-treated HMEC described in the previous chapter, non-
methylated commercial Fetal DNA (Chemicon, Billerica, MA) was also utilized.  
Amplified PCR products were verified by gel electrophoresis and sent, on ice, to 
EpigenDx, Worcester MA for subsequent pyrosequencing analysis. 
Statistical Analysis 
 The percentage of methylation at every CpG site was calculated as mC/(mC + C) 
as previously described by (Pasquali et al. 2007).  All subsequent analysis was performed 
using Stata 10: Data Analysis & Statistical Software (Statacorp LP, College Station TX).  
Linear regression analysis of methylation data for all donors was performed for both 
mean methylation scores and the individual sites with respect to donor age.  Box plots 
were generated for each CpG site of each gene analyzed.    Comparison of mean 
methylation scores was performed using student’s t-test assuming equal variance.  A two-
sided p-value of p<0.05 was considered statistically significant. 
 54  
 
Results 
Sample Processing 
 We analyzed one-hundred DNA samples from the epithelial-enriched cell fraction 
from breast milk for promoter hypermethylation of six genes.  In order to achieve this 
goal we collected one-hundred and eleven total breast milk samples.  The breast milk 
donors varied widely in terms of their age with the youngest donor at age 19 and the 
oldest at age 45 with more than half (n=64) nursing their first birth with an average infant 
age of 239 days (Table 3.2 & Figs 3.4a-c).   Utilizing a higher centrifugation speed than 
the fifty-four samples used in RNA isolation for the processing of these samples resulted 
in a 1.8 fold increase in enriched-epithelial cells with an average yield of 32,718 
enriched-epithelial cells per mL of breast milk (Table 3.2)   In contrast to the samples 
used in RNA isolation there was a strong correlation between donor age and the total 
cells isolated per mL of breast milk (Fig 3.5a).  A similar trend existed when examining 
the enriched cells per mL however this trend was not statistically significant (Fig 3.6a).  
No significant relationships were found when yields of either population of cells was 
compared to infant age (Figs 3.5b & 3.6b).  DNA isolation was then performed on both 
the enriched and depleted fraction resulting from each sample. 
DNA Isolation 
 Of one-hundred eleven samples collected nine resulted in insufficient cells to 
carry out the cell separation and subsequent DNA isolation.  Three of those nine samples 
were of insufficient volume (<10 mL) to process. Excluding these nine samples we were 
left with 102 usable DNA samples or a 94% recovery rate.   DNA yields were directly 
related (p<.0001) to the number of enriched cells (Fig 3.7a) with an average yield of 2.4 
 55  
 
µg of DNA.   Also, as was seen in the RNA isolation in the preliminary studies the DNA 
purity was correlated strongly (p<.0001) to the number of enriched cells being utilized.  
Purity of the DNA samples was variable, however the large majority (n=86) had 
A260/A280 ratios above 1.4 (Fig 3.7b).  Samples below this mark were chloroform-
phenol precipitated an additional time without a decrease in the 280 absorbance (protein) 
but due to internal controls available in the pyrosequencing analysis were still bisulfite 
modified and analyzed.   
 
Pyrosequencing Analysis 
 Each product amplified from bisulfite modified DNA was sent to EpigenDx, 
Worcester MA for subsequent pyrosequencing analysis.  For each sample a “pyrogram” 
or sequencing readout was generated based on the quantitative signal as determined by 
luciferase activity.  Each pyrogram, along with raw methylation scores for each CpG site, 
includes the expected sequencing product result, the nucleotide dispensation order, and 
the position of the internal bisulfite modification control (Figs 3.8a-c).  This particular 
control is unique to pyrosequencing analysis and allows for determination of the 
efficiency of the bisulfite modification of an analyzed template (Tost et al. 2003).  If a 
non-methylated cytosine residue is not completely bisulfite modified a false positive 
result may be generated leading to a gross over-estimation of the amount of methylation 
in a DNA sample.  The enriched fraction of 102 samples was examined for each of the 
genes of interest using this technique.  Some difficulty in PCR amplification and/or 
subsequent sequencing analysis was experienced for a small number of samples affecting 
the final sample size despite attempts to reanalyze them. 
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Examination of Methylation Mean Scores for all Six Genes. 
 For an initial analysis the calculated mean of all CpGs for a given gene was 
determined.  As mentioned previously the detection limitation of pyrosequencing is 
roughly 5%.  Values below this threshold are considered background.  The number of 
CpG sites examined varied from gene to gene and was as low as 8 for SFRP1, or as high 
as 14 for CRBP-1 (Table 3.1).  Examination of the mean scores indicated that of the six 
genes, only one, RASSF1A, showed a strong correlation to age (p=.00156).  A number of 
samples in SFRP1 and CRBP1 as well as a single sample in TMS-1 showed high levels 
of methylation (>15%) and will be discussed in the subsequent sections (Fig 3.9).  To 
determine if examination of mean scores were masking CpG site-specific trends we 
decided to examine the CpG sites in each analyzed gene individually. 
Examination of SFRP1 Methylation by CpG Site 
 The region of interest in SFRP1 encompassed 8 CpG dinucleotides.  We first 
examined the general distribution of the methylation of all samples at each individual site 
to see if we could recognize any trends.  The mean score at each individual site varied 
very slightly from 3.97% to 7.27% but the median scores indicated a general skewing of 
the methylation scores to samples with lower levels of methylation.  A number of highly 
methylated samples, most notably 7, 16, 24, 34, 36, 42, and 50 were identified as outside 
of the inner adjacent value.  (Fig 3.10a).Only donor 34 had any familial cancer history 
with a maternal aunt, paternal aunt, and a maternal grandmother diagnosed with breast 
cancer.   However, several of the other outliers had higher levels of methylation and no 
such risk factors.  Additionally, the donors were fairly young ranging from age 26 to 38 
implying some other factor was responsible for their high methylation scores.  
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Examination of each individual site and donor age showed no statistically significant 
relationships (Fig 3.10b) 
Examination of CRBP1 Methylation by CpG Site 
 The region of interest in CRBP1 we examined contained 14 CpG dinucleotides.  
We first examined the general distribution of the methylation of all samples at each 
individual site to see if we could recognize any trends.  The mean score at each individual 
site varied from 3.18% to 11.17% with CpGs 3, 6, 10, 12, 13 and 14 showing the highest 
levels of methylation.  Median values did not indicate skewing of the data in either 
direction (Fig 3.11a).  Samples 7, 71 and 78 had some of the highest site-specific scores 
but all three donors were fairly young (age 29-35), and did not indicate a familial risk of 
breast cancer.  Examination of each individual site and age showed a single correlation of 
CpG 4 and donor age (p=.0455) (Fig 3.11b). 
Examination of TMS1 Methylation by CpG Site 
 The region of interest in TMS1 we examined encompassed 12 CpG dinucleotides.  
We first examined the general distribution of the methylation of all samples at each 
individual site to see if we could recognize any trends.  The mean score at each individual 
site varied from 1.68% to 7.38% with the highest site specific scores at CpGs 4, 5, 6 and 
12.  Median scores did not indicate skewing of the data. (Fig 3.12a).  Donor 75, a 35 year 
old, had methylation scores of almost 40% for every site assayed, and although she had a 
maternal grandmother diagnosed with breast cancer there were no other prominent 
features in her questionnaire data.  Examination of each individual site and age showed 
no statistically significant relationships (Fig 3.12b) 
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Examination of CDH1 Methylation by CpG Site 
 The region of interest in CDH1 encompassed 9 CpG dinucleotides.  We first 
examined the general distribution of the methylation of all samples at each individual site 
to see if we could recognize any trends.  The mean score at each individual site varied 
from 1.65% to 6.51% with the highest methylation scores being found at sites 6, 7, and 8.  
Median values suggested no skewing of the data had occurred. (Fig 3.13a).  Donors 26, 
95 and 104 had the highest methylation values within these sites however all three donors 
were young (age 29-35) and did not indicate a history of familial breast cancer risk.   
Examination of each individual site and age showed no statistically significant 
correlations (Figure 3.13b) 
Examination of GSTPi Methylation by CpG Site 
 The region of interest in GSTPi encompassed 13 CpG dinucleotides.  We first 
examined the general distribution of the methylation of all samples at each individual site 
to see if we could recognize any trends.  The mean score at each individual site varied 
from 2.06% to 8.23% with CpGs 4, 8, 9 and 12 having some of the highest scores.  
Median scores indicated some skewing of individual sites including CpGs 1, 4, 7 and 12 
to samples with lower methylation scores (Figure 3.14a).   Samples 35, 49, 51, and 100 
had some of the highest single site scores.  Donor 35, a 38 year old, had also had a 
paternal aunt previously diagnosed with breast cancer.  The other donors were all young 
(age 23-30) without a familial history of breast cancer.  Examination of each individual 
site and age showed no statistically significant correlations (Figure 3.14b) 
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Examination of RASSF1A Methylation by CpG Site 
 The region of interest in RASSF1A encompassed 9 CpG dinucleotides.  We first 
examined the general distribution of the methylation of all samples at each individual site 
to see if we could recognize any trends.  The mean score at each individual site varied 
from 2.17% to 7.42%.  CpGs 6-9 had higher median and mean methylation scores than 
sites 1-5 (Fig 3.15a).  Two of the samples with the highest methylation scores were 
samples 3 and 14.  Donor 3 was a 42 year old donor with both a maternal aunt and 
mother diagnosed with breast cancer.  Donor 14 was a 39 year old who had a paternal 
aunt and a sister diagnosed.  RASSF1A had the strongest and most numerous site-specific 
age correlations of any of the genes examined thus far.  Specifically CpGs 1 (p=0.0195), 
5 (p=0.0101), 7 (p=0.0467) and 9 (p=0.0294) were all significantly correlated to age. (Fig 
3.15b) 
Examination of Enriched Versus Depleted Fraction Methylation 
 As some questions have arisen in terms of the purity of the enriched fraction we 
decided to test a small number of depleted fraction samples (n=44) for RASSF1A 
methylation.  In a paired comparison between the two fractions the methylation levels 
were very similar.  There were however a small number of samples that were 
significantly more highly methylated in the enriched fraction than in the depleted 
fraction.  These samples included samples 3 and 14(Fig 3.16).  Both fractions showed a 
significant correlation with donor age however the enriched fraction had a stronger 
relationship (Figs 3.17a & b).   
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Early Pregnancy and Parity 
 Along with questions about donor age we also had wanted to address the issues of 
the effect of early pregnancy and parity on DNA methylation.  In order to examine the 
question of early pregnancy the 102 samples were sub-divided into two groups.  The first 
group contained women who had their first birth at or prior to age 25 (n=21).  The other 
group consisted of women who had their first birth after the age of 25 (n=81).  
Examination of age-related DNA methylation of our six candidate genes in these two 
sample pools showed a statistically significant correlation (p=0.0034) for mean 
RASSF1A methylation and age in the early first pregnancy group (Figure 3.18a) which 
did not exist in the late first pregnancy group (Figure 3.18b).  To determine if there was a 
reduction in mean methylation scores for each gene between the two groups t-test 
comparisons were carried out.  The mean methylation score for CDH1 was significantly 
lower in the early first pregnancy (1st birth ≤ age 25) than in the late first pregnancy 
group (1st birth>25) (p<.0001).  CRBP1 scores were significantly higher in the late first 
pregnancy group, than in the early first pregnancy group (Table 3.3c).  
  The question of parity was answered in a similar way.  Without consideration for 
age the 102 samples were subdivided into women who were currently nursing their first 
infant (n=61) versus women who were nursing their 2nd or higher infant (n=41).  In this 
comparison women nursing their 2nd or higher infant had a statistically significant 
correlation between mean RASSF1A methylation and age (p=0.0475)(Fig 3.19b) whereas 
women nursing their first infant had no such correlation (Fig 3.19a). A comparison of the 
means between these two groups revealed no significant differences (Table 3.4c)   
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 To consider whether pregnancy and parity together would have a greater 
combined effect we divided the donors into two groups.  The first group consisted of 
women nursing their first infant only (n=61).   A second group was comprised of women 
who were nursing their 2nd or higher infant and who had their first full term pregnancy 
before age 25 (n=13).  There was a high correlation between the mean methylation score 
of RASSF1A for women who were nursing their 2nd or higher infant and had their first 
full term pregnancy before 25 (p=.0053) (Fig 3.20b).  No statistically significant results 
were found for the 2nd group (Fig 3.20a).  Comparison of the means of these two groups 
did not result in significant differences for any of the six genes (Table 3.5) 
 Finally, to examine whether parity without the effect of early pregnancy would 
yield a different outcome we created two groups of donors.  The first group consisted of 
women nursing their first infant only (n=61).  The second group was comprised of 
women nursing their 2nd or higher child but who had their firstborn after the age of 25 
(n=28).  Interestingly, two previously unseen relationships were discovered.  Both GSTPi 
(p=0.0460) and SFRP1 (p=0.0758) had a relationship to age in the group nursing their 2nd 
or higher child, however only GSTPi had a significant correlation (Fig 3.21b) No 
statistically significant results were found for the 1st infant group (Fig 3.21a) Comparison 
of the means between these two groups resulted in no significant difference of the means 
for any of the six genes (Table 3.6). 
Discussion 
 In this report we analyzed age-associated promoter hypermethylation patterns in 
DNA isolated from the epithelial-enriched cell fraction from breast milk.  Of the six 
genes assayed only one gene, RASSF1A, had a statistically significant correlation 
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between mean methylation score and donor age.  As RASSF1A was one of two genes in 
our panel to have previously shown age-related trends, and the only gene to show such a 
relationship in breast tissue, this result was quite promising.  Euhus et al (2008) 
determined that in benign breast cells from fine-needle aspiration biopsy RASSF1A 
methylation score increased with women’s age (range: 32 to 55).  The importance of age-
related methylation trends in normal tissue has been highlighted in several different ways.  
One such revelation was that regions frequently found to be hypermethylated in 
neoplastic colorectal cells were also found to be methylated to a much lesser degree in 
normal adjacent tissue in an age-related manner (Issa 2003).  A similar trend has since 
been observed in a paired study looking at cancerous prostate tissue and adjacent normal 
tissue (Kwabi-Addo et al. 2007).  This suggests that DNA methylation accumulates over 
time and may precede and predispose to a full-blown malignancy.  Indeed, the study by 
Euhus found that increased methylation of RASSF1A in benign breast tissue was highly 
correlated to breast cancer risk and atypical cytology.   
 The highly quantitative data obtained by this analysis has allowed us to examine 
mean methylation scores as well as to perform analysis on the relationships localized to 
individual CpG sites with respect to donor age.  Examination of the CpG sites 
individually has revealed the RASSF1A and age relationship to be stronger for some 
CpG sites analyzed than others    These included CpGs 1, 5, 7 and 9 (Fig 3.15b).  The 
significance of this result remains to be seen, but it supports previously published 
findings that some CpG sites are more frequently methylated than others. (Yan et al. 
2003; Shaw et al. 2006).  Many of these observations have arisen due to quantitative 
technological advances such as pyrosequencing however the significance of such 
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phenomenon is currently unknown.  In the paper by Shaw et al (2006), they state that 
there is an observable trend towards lower methylation at any CpG located only a few 
nucleotides away from a CpG with high methylation.  They and their colleagues postulate 
that it may be that the steric hindrance of DNA methylase does not allow equally high 
methylation of two closely adjacent sites.  In our analysis of the enriched-epithelial DNA 
we found that significant trends with specific RASSF1A CpG sites and age did not occur 
on adjacent sites.  Whether this is a significant finding or is a coincidence is a matter of 
discussion.  Shaw’s group further claimed that site-specific methylation is characteristic 
of promoters of the genes which they examined and are reproducible between tumor 
samples to such a degree that an analysis of mean methylation scores is still valuable.  
However, they do not suggest a mechanism for how DNA methylation accumulates in the 
promoter over time in normal tissues or whether early methylation of specific sites may 
indicate disease susceptibility. 
 Yan et al (2003) reported the possibility of a “methylation wave” occurring in 
RASSF1A which progressively extended from the first exon into the promoter region of 
the gene.  They reported that most of the normal breast tissue studied had methylated 
CpGs in the portion of the CpG island extending into the first exon, but little methylation 
in the sites within the promoter.  In tumor samples both areas were heavily methylated 
suggesting that the barrier separating these two regions is lost.  In our analysis the region 
examined for RASSF1A corresponded to this boundary region.  Specifically sites 1-3 fell 
within the promoter region of the gene and sites 4-9 were within the portion of the CpG 
island extending into the first exon.  In agreement with Yan’s findings the majority of the 
sites we examined in the first exon (CpGs 6-9) had higher mean and median methylation 
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scores than the other sites assayed.  Two samples with high levels of site-specific 
methylation were samples 3 and 14.  These samples not only had high methylation in the 
CpGs within the 1st exon, but also had very high single-site methylation in CpG 1 of the 
promoter.   Interestingly both samples were from donors corresponding to the 90th 
(Sample 14) and 95th (Sample 3) percentiles of age groups.  Additionally, both donors 
had an extensive familial history of breast cancer.   To date, longitudinal studies 
examining the progressive time-dependant nature of epigenetic events across individual 
sites in a CpG island have not been performed.   As such it is difficult to surmise what the 
importance of site-specific methylation in normal cells can be.     
 Samples 3 and 14 were also the two standout samples in the comparison between 
RASSF1A methylation of the enriched and depleted cell fractions.  If eliminated from the 
comparison the statistical significance of the comparison is p<.0001.  This suggests that 
although methylation can be detected in both cell fractions, there are samples which 
exhibit high levels of methylation only in the enriched-epithelial fraction.  Analysis of the 
remaining negative fraction samples could shed more light on this situation as only forty-
four of the one hundred and two samples have been examined, and only for RASSF1A.   
 Having seen a strong relationship of RASSF1A and age in these cells we were 
interested in how early pregnancy and parity might affect these trends, and if by 
examining different clusters of samples we could see age correlations with other genes.  
As both pregnancy and lactation result in a decreased risk for breast cancer (Newcomb 
1997; Lipworth et al. 2000; Russo et al. 2005) we expected to see stronger age trends in 
groups that had either only had one birth, or had given birth after age 25.  What we 
observed was that RASSF1A methylation levels were significantly correlated to 
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increased age in both the early pregnancy (first birth before age 25) and parity (more than 
2 live births) groups (Figs 3.18a, 3.19b & 3.20b).  This was contrary to our expectations 
and appeared to suggest that RASSF1A methylation was independent of the protective 
roles of both reproductive factors.  Clustering the groups by age at first birth and number 
of live births revealed a relationship that were not previously seen in the examination of 
means or specific sites.  Women who had their first birth after age 25 and were currently 
nursing their 2nd or higher birth had age-associated decreases in methylation of GSTPi 
(Fig 3.21b).   The observed relationships appeared to be gene-specific however an 
explanation for why this particular gene would have a pregnancy or lactation associated 
relationship has been elusive. 
  In addition to our questions concerning age-related trends we hypothesized that 
early pregnancy (before 25) & parity (2 or more live births) would result in a decreased 
mean methylation score for the donors within these groups.    The comparison of means 
resulted in two significant findings suggesting that age of first birth before 25 correlates 
to a decrease in mean CRBP1 methylation and an increase in mean CDH1 methylation.  
The decrease in CRBP1 methylation is interesting as expression of this gene has been 
reported by the Smith Schneider lab to be induced in pregnancy. The increase in CDH1 
methylation is perplexing however as loss of CDH-1 expression is frequently associated 
with poor prognosis due to increased invasiveness and metastatic potential (Caldeira et 
al., 2006; Berx et al., 2001).  
 The relationships we have determined to exist between methylation and 
parity/early pregnancy must be scrutinized carefully due to the mean methylation scores 
being so close to the detection level of the instrument (5%).  As such it is difficult to 
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determine whether the findings were truly significant or not.  Analysis of the largely 
unmethylated controls sent out along with each batch of sequencing reactions indicates 
variability of the sequencing results does occur (Fig 3.22).  This variation seems minimal 
and does not change drastically at or below 5%.  The mean methylation scores for each 
test were not significantly different leading us to believe that results at low levels of 
methylation are reliable.  In addition to the low mean scores which could result in false 
positive results, there were a number of samples with high methylation scores which 
could possibly be producing some of these relationships we have seen in the parity and 
early pregnancy analysis due to the small sample size of some of the groups.  As such, 
caution is warranted when analyzing the trends we have observed. 
 We have used pyrosequencing technology to examine the epigenetic profile of 
enriched-epithelial cells from breast milk.  Our data indicates the presence of both mean 
and site-specific age-related trends with RASSF1A as has been reported in other studies.  
To our knowledge this is the first study to attempt to directly examine the relationship 
between the protective effects of pregnancy to DNA hypermethylation.  Although several 
relationships were uncovered, the significance of each is a matter of debate and no clear 
conclusions can be drawn.  Breast milk samples from a larger pool of high-risk donors 
and/or cancerous patients would likely help to strengthen many of the observations that 
we have made.  However, we have shown that breast milk and the cells contained within 
are valuable sources of biomarker material  
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Table 3.1 Pyrosequencing primers and cycle conditions.   
 
Gene 
Name  Sequences 
# of 
CpGs Cycle Conditions 
 (Source) 
      
  
      
GSTPi Forward  – 5’- GGGGYGGGATTATTTTTATAAG – 3’ 13 95ºC 15 min;  
(Biotage) Reverse  5' – Biotin - AATTAACCCCATACTAAAAACTCT – 3’ 
45 x (95ºC 30 s; 55ºC 
30 s; 72ºC 30 s); 
 Sequencing  – 5’ – GGATTATTTTTATAAGGT – 3’  72ºC 5 min; 4°C Hold 
  
      
  
      
CDH1 Forward  – 5´-ATTTTAGTAATTTTAGGTTAGAGGGTTA - 3’ 9 95ºC 15 min;  
(Biotage) Reverse  5' – Biotin -ACCACAACCAATCAACAAC – 3’  
45 x (95ºC 30 s; 52ºC 
30 s; 72ºC 30 s); 
 Sequencing  – 5´-ATTTTAGGTTAGAGGGTTAT – 3’  72ºC 5 min; 4°C Hold 
  
      
  
      
RASSF1 Forward  – 5´- AGTTTGGATTTTGGGGGAGG - 3’ 9 95ºC 15 min;  
(Biotage) Reverse  5' – Biotin – CAACTCAATAAACTCAAACTCCCC – 3’ 
45 x (95ºC 30 s; 55ºC 
30 s; 72ºC 30 s); 
 Sequencing  – 5´- GGGTTYGTTTTGTGGTTT – 3’  72ºC 5 min; 4°C Hold 
  
      
  
      
SFRP1 Forward  5’ - GAGTCGCGTTTGGTTTTAGTAAA  – 3’ 8 95ºC 15 min;  
(EpigenDx) Reverse  5’ – Biotin – AACTCCTACCACCAAACCCTC – 3’ 
 
45 x (95ºC 30 s; 51ºC 
30 s; 72ºC 30 s); 
 Sequencing  5’- GTTTGGTTTTAGTAAAT – 3’ 
 
72ºC 5 min; 4°C Hold 
  
      
  
      
CRBP1 Forward  5’ – GGGAGGAGAGATAGTTATAATGGATT – 3’ 14 95ºC 15 min;  
(EpigenDx) Reverse  5’ – Biotin - CCAACATCTTCCAATACCCAATAA – 3’ 
45 x (95ºC 30 s; 51ºC 
30 s; 72ºC 30 s); 
 Sequencing 5’ – ATGGATTTTCTYGTAGGT – 3’ 
 
72ºC 5 min; 4°C Hold 
  
      
  
      
TMS-1 Forward  5’ – GGAGATTAGAGTGGGAGGAA  – 3’ 12 95ºC 15 min;  
(EpigenDx) Reverse  5’ – Biotin - CACCCACAACAACTTCAACTTAA – 3’  
45 x (95ºC 30 s; 56ºC 
30 s; 72ºC 30 s); 
 Sequencing 5’ – TTTGGTAGGAGGTTGTA – 3’  72ºC 5 min; 4°C Hold 
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Table 3.2 Cell counts of total and epithelial-enriched fractions along with donor 
demographics of 102 samples utilized in the subsequent DNA isolation.   
*Total cell counts were available on 90 of 102 samples.   
 
 
 
 
 Cell Separation Information 
    
 
Mean Std Dev n 
Total Cells 16,019,350 19,510,481 *90 
Total Cells / mL 203,094 288,634 *90 
Enriched Cells 2,510,253 2,951,516 102 
Enriched Cells / mL 32,718 42,547 102 
Volume 86 33 102 
    
 
Donor Demographics 
    
 
Mean Std Dev N 
Donor Age (Years) 32 6 102 
Babys Age (Days) 239 177 102 
Live Births 1.55 0.82 102 
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Table 3.3 Statistical data extracted from figure 3.18 examining the effect of early 
pregnancy on mean methylation levels.  
(a) donors who had their first birth at or before age 25 (b) donors who had their first birth 
after age 25 (c) Student t-test comparison between the means of each gene for both 
groups.  The means of both CDH1 and CRBP1 were statistically different (p<.0001) with 
the mean for CDH1 increasing slightly in the early pregnancy group and the mean for 
CRBP1 decreasing. 
 
(b)      
1st birth </= 25 n= Mean 
Std 
Dev Min Max 
RASSF1A 21 4.80 2.85 0.92 15.37 
TMS-1 21 2.90 1.10 1.12 5.37 
SFRP1 21 5.25 6.20 1.84 31.33 
GSTPi 19 3.59 0.85 1.84 4.53 
CDH1 20 6.27 2.09 2.70 10.12 
CRBP1 20 3.51 1.28 1.57 6.57 
(b)      
1st birth > 25 n= Mean 
Std 
Dev Min Max 
RASSF1A 81 4.70 3.42 0.70 22.89 
TMS-1 79 3.88 4.26 1.07 39.28 
SFRP1 80 5.94 5.56 1.12 33.02 
GSTPi 80 3.65 1.04 1.92 7.05 
CDH1 73 3.57 1.80 0.54 9.66 
CRBP1 77 6.55 3.11 1.55 18.82 
      
(c )      
Comparison of Means dF p-value t= 
  
RASSF1A 100 0.91 0.12   
TMS-1 97 0.30 -1.04   
SFRP1 99 0.62 -0.49   
GSTPi 97 0.82 -0.23   
CDH1 91 <0.0001 5.74   
CRBP1 95 <0.0001 -4.27   
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Table 3.4 Statistical data extracted from figure 3.19 examining the effect of parity 
on mean methylation levels.  
(a) donors who have only had one child (b) donors who have had 2 or more children (c) 
Student t-test comparison between the means of each gene for both groups.  No statistical 
differences were found between the means of the two groups 
 
(a)      
First birth only N Mean Std Dev Min Max 
RASSF1A 61 4.37 2.72 0.70 19.70 
TMS-1 59 3.35 1.30 1.07 7.79 
SFRP1 60 6.30 5.92 1.12 31.33 
GSTPi 58 3.55 1.05 1.84 7.05 
CDH1 56 3.49 1.68 0.54 8.17 
CRBP1 58 6.64 3.14 1.55 18.82 
(b)      
Second birth or higher N Mean Std Dev Min Max 
RASSF1A 41 5.24 3.97 0.92 22.89 
TMS-1 41 4.13 5.79 1.51 39.28 
SFRP1 41 5.07 5.07 1.52 33.02 
GSTPi 41 3.76 0.92 1.92 6.41 
CDH1 37 3.66 1.74 0.78 9.66 
CRBP1 39 6.28 2.59 2.15 12.99 
(c )      
Comparison of Means dF p-value t=  
 
RASSF1A 100 0.19 -1.31   
TMS-1 97 0.32 -1.00   
SFRP1 99 0.28 1.08   
GSTPi 97 0.31 -1.03   
CDH1 91 0.64 -0.47   
CRBP1 95 0.55 0.59   
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Table 3.5 Statistical data extracted from figure 3.20 examining the combined effect 
of parity and lactation on mean methylation levels.   
(a) donors who have only had one child (b) donors who have had 2 or more children and 
had their first at or before age 25 (c) Student t-test comparison between the means of each 
gene in the two groups.  No statistical differences were found between the means of the 
two groups 
 
(a)      
First birth only n= Mean 
Std 
Dev Min Max 
RASSF1A 61 4.37 2.72 0.70 19.70 
TMS-1 59 3.35 1.30 1.07 7.79 
SFRP1 60 6.30 5.92 1.12 31.33 
GSTPi 58 3.55 1.05 1.84 7.05 
CDH1 56 3.49 1.68 0.54 8.17 
CRBP1 58 6.64 3.14 1.55 18.82 
(b)      
1st birth </= 25, 2nd or 
higher n= Mean 
Std 
Dev Min Max 
RASSF1A 13 4.96 3.55 0.92 15.37 
TMS-1 13 2.90 1.18 1.54 5.37 
SFRP1 13 3.97 1.72 1.84 7.18 
GSTPi 13 3.68 0.79 2.57 4.93 
CDH1 12 3.67 1.47 1.57 6.57 
CRBP1 12 6.46 2.40 2.70 10.12 
(d)      
Comparison of Means dF p-value t= 
  
RASSF1A 100 0.50 0.67   
TMS-1 97 0.26 -1.15   
SFRP1 99 0.17 -1.40   
GSTPi 97 0.68 0.42   
CDH1 91 0.73 0.34   
CRBP1 95 0.85 -0.19   
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Table 3.6 Statistical data extracted from figure 3.21 examining the combined effect 
of parity and lactation on mean methylation levels.   
(a) donors who have only had one child (b) donors who have had 2 or more children and 
had their first birth after age 25 (c) Student t-test comparison between the means of each 
gene in the two groups.  No statistical differences were found between the means of the 
two groups 
 
(a)      
First birth only n= Mean 
Std 
Dev Min Max 
RASSF1A 61 4.37 2.72 0.70 19.70 
TMS-1 59 3.35 1.30 1.07 7.79 
SFRP1 60 6.30 5.92 1.12 31.33 
GSTPi 58 3.55 1.05 1.84 7.05 
CDH1 56 3.49 1.68 0.54 8.17 
CRBP1 58 6.64 3.14 1.55 18.82 
(b)      
1st birth > 25, 2nd or 
higher n= Mean 
Std 
Dev Min Max 
RASSF1A 28 5.37 4.21 1.32 22.89 
TMS-1 28 4.7 6.92 1.51 39.28 
SFRP1 28 5.6 5.98 1.52 33.02 
GSTPi 28 3.79 0.99 1.92 6.41 
CDH1 25 3.66 1.88 0.78 9.66 
CRBP1 27 6.19 2.71 2.15 12.99 
(c )      
Comparison of Means dF p-value t= 
  
RASSF1A 100 0.18 1.35   
TMS-1 97 0.15 1.45   
SFRP1 99 0.61 -0.51   
GSTPi 97 0.31 1.01   
CDH1 91 0.69 0.41   
CRBP1 95 0.52 -0.64   
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Figure 3.1 PCR bias testing of SFRP1 was carried out to ensure equal amplification 
of both methylated and unmethylated templates.   
In vitro methylated DNA (IVM) was mixed with unmethylated normal blood leukocyte 
DNA at 0, 5, 10, 25, 50, 75 and 100%.  Observed methylation scores (y-axis) were 
plotted and the expected methylation scores (x-axis).  The first set of SFRP1 primers 
preferentially amplified unmethylated DNA and was subsequently redesigned. 
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Figure 3.2 PCR bias testing of CRBP1 which was carried out to ensure equal 
amplification of both methylated and unmethylated templates.   
In vitro methylated DNA (IVM) was mixed with unmethylated normal blood leukocyte 
DNA at 0, 5, 10, 25, 50, 75 and 100%.  Observed methylation scores (y-axis) were 
plotted and the expected methylation scores (x-axis).   
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Figure 3.3 PCR bias testing of TMS-1 which was carried out to ensure equal 
amplification of both methylated and unmethylated templates.   
In vitro methylated DNA (IVM) was mixed with unmethylated normal blood leukocyte 
DNA at 0, 5, 10, 25, 50, 75 and 100%.  Observed methylation scores (y-axis) were 
plotted and the expected methylation scores (x-axis).   
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Figure 3.4 Histograms of donor and infant demographics.   
Distributions of (a) donor age (b) infant age and (c) live births 
 
n=102
0
2
4
6
8
10
Fr
e
qu
e
n
cy
20 25 30 35 40 45
Donor Age (Years)
a.
n=102
0
5
10
15
Fr
eq
u
e
n
cy
0 200 400 600 800
Infant Age (Days)
b.
n=102
0
20
40
60
Fr
eq
u
en
cy
1 2 3 4 5
Live Births
c.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77  
 
Figure 3.5 Relationship between total cells per mL of breast milk and (a) the 
donor’s age and (b) nursing length.   
Total cells counts were only taken on 90 samples as previously mentioned.  Shaded 
region indicates 95% confidence interval. 
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Figure 3.6 Relationship between enriched epithelial cells per mL of breast milk and 
(a) the donor’s age and (b) nursing length.   
Shaded region indicates 95% confidence interval. 
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Figure 3.7 Relationship between enriched epithelial yield and (a) DNA yield and (b) 
DNA purity.   
Both factors were significantly correlated to enriched cell population yields.  Shaded 
region indicates 95% confidence interval. 
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Figure 3.8 Example Pyrogram readouts for RASSF1A.   
When the sequence to analyze is entered into the Pyrosequencing analysis software, it 
generates (a) theoretical outcome histogram (annotated on the top with the actual 
sequence) and the nucleotide dispensation order (x-axis) based on the information 
entered. The nucleotides dispensed at positions 1, 4, 8, 12, 22, 32, 40, 46, and 54 are 
negative dispensation controls which should not be incorporated into the template and 
control for non-specific binding.  The cytosine dispensed at position 19 is an internal 
control for bisulfite modification.  In a fully bisulfite modified sample this particular site 
should result in no quantitative signal.  If the unknown sequencing result does not match 
the theoretical or fails either the bisulfite or negative dispensation controls, the reaction is 
failed. (b) Fetal DNA (c) in vitro methylated DNA (d) no template (water) control.  At 
the top left corner of each figure is the expected sequencing product with possible 
methylated sites denoted by a “Y”. 
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Figure 3.9 Mean methylation scores for each of six genes analyzed with age.   
Sample size varied among the genes examined due to failure of some samples to pass the 
internal bisulfite modification control (>7% incomplete conversion) mentioned 
previously in Fig 3.8.  Re-sequencing these samples gave an identical result.  
Examination of mean methylation scores resulted in only one significant correlation to 
donor age with RASSF1A.   There were however a number of high methylation samples 
in SFRP1 and CRBP1 as well as a single high methylation score for TMS-1.  Shaded 
region indicates 95% confidence interval. 
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Figure 3.10 CpG site-specific analysis of SFRP1 promoter methylation.   
(a) box plot showing the distribution of methylation for all samples analyzed (n=101).  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area.  (b) Linear 
regression plots for each of the 8 CpG sites and age.   
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Figure 3.11 CpG site-specific analysis of CRBP1 promoter methylation.  
(a) box plot showing the distribution of methylation for all samples analyzed (n=97).  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area.    (b) Linear 
regression plots for each of the 14 CpG sites and age.  CpG 4 alone showed a correlation 
to age. 
 
0
10
20
30
40
50
%
 
M
e
th
yla
tio
n
CRBP1 Methylation by CpG Site
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Mean
 
 
p=0.1603
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 1
p=0.1065
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 2
p=0.8099
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 3
p=0.0455
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 4
p=0.7234
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 5
p=0.6462
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 6
p=0.3484
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 7
p=0.1619
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 8
p=0.3339
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 9
p=0.6567
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 10
p=0.9414
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 11
p=0.8882
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 12
p=0.1258
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 13
p=0.6512
0
10
20
30
40
50
M
e
an
 
%
 
M
et
hy
la
tio
n
20 25 30 35 40 45
Age of Donor
CpG 14
CRBP1 Site-Specific Methylation By Donor Age, n=97
 
a. 
b. 
 84  
 
Figure 3.12 CpG site-specific analysis of TMS-1 promoter methylation.   
(a) box plot showing the distribution of methylation for all samples analyzed (n=100)  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area. (b) Linear 
regression plots for each of the 12 CpG sites and age.   
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Figure 3.13 CpG site-specific analysis of CDH1 promoter methylation.   
(a) box plot showing the distribution of methylation for all samples analyzed (n=93).  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area.  (b) Linear 
regression plots for each of the 9 CpG sites and age.   
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Figure 3.14 CpG site-specific analysis of GSTPi promoter methylation.   
(a) box plot showing the distribution of methylation for all samples analyzed (n=99).  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area. (b) Linear 
regression plots for each of the 13 CpG sites and age.   
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Figure 3.15 CpG site-specific analysis of RASSF1A promoter methylation.   
(a) box plot showing the distribution of methylation for all samples analyzed (n=102).  
Boxes include 50% of all observations and the median (horizontal line).  Box hinges 
indicate the 25th and 75th percentiles.  Whiskers (adjacent values) indicate 1.5x the 
interquartile range, with outliers marked as circles outside of this area.  (b) Linear 
regression plots for each of the 9 CpG sites and age.  CpGs 1, 5, 7 and 9 were 
significantly correlated to age. 
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Figure 3.16 Comparison of the RASSF1A mean methylation levels in enriched 
fraction versus depleted fraction cells.   
A high correlation existed between the methylation of the two fractions, however there 
were some outliers that could illustrate the importance of the cell separation.  Shaded 
region indicates 95% confidence interval. 
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Figure 3.17 Mean RASSF1A methylation scores of the (a) enriched and (b) depleted 
fractions with respect to age.  
Both fractions show a significant correlation with donor age however the enriched 
fraction showed a stronger relationship.  Shaded region indicates 95% confidence 
interval. 
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Figure 3.18 Examination of how early pregnancy affects DNA hypermethylation. 
(a) mean methylation scores for women who had their first birth at or before age 25  
(b) mean methylation scores for women who had their first birth after age 25.  A 
significant correlation existed between mean RASSF1A methylation scores and age with 
women who had their first birth before 25.  Additionally women who gave birth after the 
age of 25 have higher levels of SFRP1 methylation than the early pregnancy group 
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Figure 3.19 Examination of how parity may affect DNA hypermethylation.   
(a) mean methylation scores for women nursing their first birth (b) mean methylation 
scores for women who are currently nursing their 2nd or higher child.  Women nursing 
their 2nd or higher child had a significant correlation between mean RASSF1A 
methylation score and age.  SFRP1 and CRBP1 have a number of samples with high 
mean methylation scores in the first birth group as compared to the other. 
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Figure 3.20 Examination of how the combined effects of early pregnancy and parity 
may affect DNA hypermethylation as compared to women who have only given 
birth once.   
(a) donors nursing their first birth only (b) women nursing their second or higher birth 
and who had their first at or before age 25.  Although the sample size is small there was 
an age-related trend with RASSF1A in the early pregnancy and lactation group.   
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Figure 3.21 Examination of how lactation, but not early pregnancy would affect 
mean methylation scores.   
(a) donors nursing their first birth only (b) women nursing their second or higher birth 
and who had their first birth after age 25.   Both GSTPi and SFRP1 showed a relationship 
with age, however only GSTPi had a significant correlation. 
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Figure 3.22 Reproducibility test of pyrosequencing analysis at low methylation 
levels.   
The same fetal DNA sample was included as a control for each batch of sequencing.  
Each PCR and sequencing analysis for RASSF1A was carried out independently months 
apart.  Methylation scores of less than 5 % are not as closely clustered as methylation 
scores above 5% however they are still fairly close.  (a) % methylation for each CpG (b) 
Box plots for each of 3 runs 
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